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Abstract: BACKGROUND & AIMS: Ischemia-reperfusion injury (IRI) can cause hepatic failure
after liver surgery or transplantation. IRI causes oxidative stress, which injures
sinusoidal endothelial cells (SECs), leading to recruitment and activation of Kupffer
cells and platelets (by unknown processes) and microcirculatory impairment. We
investigated whether injured SECs release microparticles (small fragments shed from
outer leaf of the plasma membrane) with inflammatory effects that contribute to IRI
pathogenesis.
METHODS: C57BL6 mice underwent 60min of partial hepatic ischemia followed by
15min-24hrs of reperfusion. We collected blood and liver samples, isolated and
measured circulating microparticles, and determined protein and lipid content. In
mouse primary hepatocytes, we investigated features of microparticles and
mechanisms of production. We analyzed the effects of an annexin V-homodimer
(diannexin or ASP8597) on post-ischemia microparticle production and function.
RESULTS: Circulating microparticles released 15-30min after ischemic reperfusion
contained markers of SECs, platelets, natural killer T cells, and CD8+ cells; 4 hrs later,
they contained markers of macrophages. Microparticles also contained F2-
isoprostanes, markers of oxidative damage to membrane lipids. Injection of mice with
TNF-alfa increased formation of microparticles, whereas injection with diannexin
substantially reduced release of microparticles and prevented IRI. Hypoxia followed by
re-oxygenation of primary hepatocytes generated microparticles via processes that
involved oxidative stress and Ca2+. Circulating microparticles were engulfed by
cultured hepatocytes, injuring them via the mitochondrial membrane permeability
transition. Microparticles also activated platelets and induced migration of inflammatory
cells in vitro. The inflammatory properties of microparticles involved activation of the
transcription factor NF-kB, JNK and increased levels of E-selectin, P-selectin, Icam1,
and Vcam1; these processes were blocked by coating microparticles with Diannexin.
CONCLUSIONS: Following ischemia and reperfusion of mouse liver, microparticles
(derived from SECs, platelets, and lymphocytes) are taken up by hepatocytes, where
they activate signaling pathways that mediate inflammation and hepatocyte injury.
Diannexin prevents microparticle formation and subsequent inflammation.
Order of Authors: Narci Teoh
Hussam Ajamieh
Heng Jian Wong
Kevin Croft
Trevor Mori
Anthony Allison
Geoffrey Charles Farrell
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
Suggested Reviewers: Han-Kiat Ho, PhD
Associate Professor, National University of Singapore, Agency for Science Technology
and Research Singapore
phahohk@nus.edu.sg
Expertise in liver injury, hepatic pathobiology/signalling pathways, therapeutics,
oxidative stress, liver inflammation, Kupffer cells, mitochondria
Michal Heger, MD PhD
Professor, University of Amsterdam
m.heger@amc.uva.nl
Expertise in liver ischaemia reperfusion injury, hepatic surgery, liver
pathophysiology/signalling pathways, inflammation, hepatoprotective strategies against
liver injury, sinusoidal endothelial cells
Emanuele Albano, MD PhD
Chair, University of Amedeo Avogadro of East Piedmont
emanuele.albano@med.unipmn.it
Expertise in liver ischaemia reperfusion injury, hepatic surgery, hepatoprotection,
inflammation, liver pathophysiology, microcirculation, sinusoidal endothelial cell,
inspired this article
Antony Wheatley, MD PhD
Chair, National University of Ireland
antony.wheatley@nuigalway.ie
Expertise in microcirculation, inflammation, platelets, Kupffer cells, oxidative stress,
liver pathophysiology, animal models of liver injury, ischemia reperfusion injury
Hartmut W Jaeschke, PhD
Professor, University of Kansas Medical Center
hjaeschke@kumc.edu
Expertise in liver inflammation, Kupffer cells, oxidative stress, liver injury signalling
pathways, hepatoprotection, therapeutic interventions against hepatic ischemia
reperfusion injury
Peter Angus, MD PhD
Director, The Austin Hospital
peter.angus@austin.org.au
Expertise in liver surgery, transplantation, ischaemia reperfusion injury, animal models,
hepatic inflammation, Kupffer cells, microcirculation, sinusoidal endothelial cells
Opposed Reviewers: Detlef Schuppan, MD PhD
Mainz University Medical Center and Harvard
detlef.schuppan@unimedizin-mainz.de
Competitor and unable to provide an unbiased assessment
Response to Reviewers: 21st June 2014
Professor Thiruma V. Arumugam, PhD
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PLOS ONE
Dear Professor Arumugam,
Re: PONE-D-14-14438
Microparticles mediate hepatic ischemia-reperfusion injury and are the targets of
Diannexin (ASP8597)
Thank you for your letter dated 9th May 2014. We are grateful that you consider our
manuscript will likely be suitable for publication, and we are now pleased to submit a
revised version addressing all the points stipulated. We also enclose a ‘point-by-point’
response to the two reviewers’ comments.
There are no changes to our financial disclosures. Unfortunately one of the authors,
Emeritus Professor Anthony Allison passed away in February 2014. We understand he
was no longer a financial employee of Alavita Inc 2 years earlier (ie. January 2012) so
clearly, there was no impression of potential conflict of interest. We have noted the late
Emeritus Professor Allison’s passing by indicating ‘deceased’ after his name in the
author list and by a footnote; we would be grateful if you would allow us to insert a brief
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tribute to his memory (1 sentence dedication) in the front pages of the manuscript.
We have uploaded a clean revised manuscript as our 'Manuscript' file, and a marked-
up copy of the changes made (changes underlined) from the previous article file as a
'Revised Manuscript with Track Changes' file.
Thank you for considering this revised version for publication in PLOS ONE.
Yours sincerely,
Narci Teoh and Geoff Farrell,
on behalf of all the authors
Point-by-Point Responses (in italics)
JOURNAL REQUIREMENTS
When submitting your revision, we need you to address these additional requirements.
1. We noticed that you did not deposit your data to a publicly available database, or
include it in the submission form. All PLOS journals now require raw data underlying
the findings described in the manuscript to be freely available to other researchers,
either in a public repository, or in the manuscript itself. Should your paper be accepted
for publication, you must state exactly where your data is deposited, and provide
accession numbers or DOIs.
Thank you for the reminder. Our data in the revised manuscript has been submitted to
the Australian National University’s Research Data Repository called ‘ANU Research’
and is now freely accessible by interested members of the public. ANU Research can
be found here at https://www.anu.edu.au/research/access/index.php.
Email confirmation from ‘ANU Research’ (data repository coordinator: Katy Najafi) has
been appended in the submission as evidence.
2. Please amend either the title on the online submission form (via Edit Submission) or
the title in the manuscript so that they are identical.
This has been amended online to reflect the title in the manuscript:
“Microparticles mediate hepatic ischemia-reperfusion injury and are the targets of
Diannexin (ASP8597)”
3. Please include your tables as part of your main manuscript and remove the
individual files. Please note that supplementary tables (should remain/ be uploaded) as
separate "supporting information" files.
Table 1 is now part of the main manuscript (pg 32). The supplementary tables have
remained as separate “supporting information” files.
4. Thank you for stating the following in the Competing Interests section: "The authors
have declared that no competing interests exist”. We note that one of the authors is
employed by a commercial company ‘Alavita Inc’.
We wish to clarify that this declaration still holds and that there are no changes to our
financial disclosures. Emeritus Professor Anthony Allison sadly passed away in
February 2014. He ceased to be an employee of Alavita Inc 2 years prior, due to ill
health (ie. was no longer financially paid by Alavita Inc from January 2012) so clearly,
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there was no impression of potential conflict of interest at the time when the Diannexin
experiments were performed, and when the manuscript was written and submitted in
2014. We have noted the late Professor Allison’s passing by indicating ‘deceased’ after
his name in the author list.
REVIEWERS’ COMMENTS
We thank both reviewers for their general comments and their responses to the
journal’s questions.
We note Reviewer 1’s response to question 4 as follows:
4. Is the manuscript presented in an intelligible fashion and written in standard
English?
Reviewer #1: No
Reviewer #2: Yes
Reviewer 1 has raised concerns about clarity and flow of ideas in the article. We agree
there are several experimental approaches that analyse the subject (eg. formation and
pathogenicity of microparticles [MPs] in liver ischemia-reperfusion injury [IRI]) in
considerable detail, as acknowledged by Reviewer 2’s general comments. This will
place a challenge for the reader unless our rationale for each approach is clearly
stated.
With the assistance of specific comments made by the reviewers, we have carefully re-
written much of the manuscript to improve its readability. We thank the reviewers for
bringing this to our attention and trust the paper now achieves the high standards
sought by PLOS ONE.
5. Reviewer Comments to the Author
Reviewer #1: PONE-D-14-14438
The authors have used a murine model of hepatic ischemia/reperfusion injury (IRI) to
characterize the cellular source and biological effects of microparticles (MPs) in post-
ischemic liver inflammation. It is shown that MPs originate during early reperfusion
from nearly all IRI-pertinent cell types, are directly toxic to hepatocytes, are leukocyte
chemoattractants, and have the ability to activate platelets. The release as well as the
pro-inflammatory effects of MPs could be attenuated by administering the Annexin V
homodimer Diannexin, which reportedly does so by shielding phosphatidylserine (PS)
residues exposed on the MP outer membrane leaflet.
Strength:
The major strength of the manuscript is that it sheds light on a completely novel
pathophysiological aspect of hepatic IRI. The characterization of MPs is very thorough
and provides for an interesting therapeutic avenue. The work performed falls within the
high level of research that is expected from the Farrell and Teoh group.
Thank you for these very positive and encouraging comments.
Weakness:
The most important drawback of the manuscript is that the rationale for some of the
performed experiments is not always clear, which makes the paper difficult to follow at
times. A large variety of parameters have been measured without placing the (often
very interesting) findings in context of the rest of the data. The manuscript would
benefit from a more comprehensive and accessible/focused presentation of data and a
more in-depth discussion.
The authors have noted these constructive comments. We acknowledge “clunky” areas
in the manuscript where we rapidly switched ‘gears’ ie. concepts or experimental
platforms, for example, from in vivo to in vitro systems, or from injury to inflammation.
With the reviewer 1’s help in identifying some of these areas, we have made very
substantive changes to improve the clarity and logical flow of the article. With these
comments in mind, we have given considerable thought to an extensive revision of the
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
discussion; these amendments are underlined in the revised version.
Minor comments:
Introduction. Kindly note: we have changed the bullet points to numbers for ease of
reference to our responses.
1) “these adhere to SECs … factor- (TNF)”. The leukocyte recruitment paradigm differs
between the sinusoids (SECs) and post-sinusoidal venules, especially with respect to
endothelial leukocyte receptors. Please verify whether the mentioned adhesion
molecules are indeed expressed on SECs and if they are relevant for liver IRI/sterile
inflammation (see, e.g., PMIDs 22064428, 22982943).
We have checked the 2 recent references cited and are very familiar with references 1
- 6 in the manuscript (one by us) which we cite in favour of this point. Yes, the stated
adhesion molecules are expressed on SECs and are relevant to liver sterile
inflammation and IRI.
2) “We have described … pro-thrombotic responses in hepatic IRI”. To our knowledge,
very few papers have clearly shown activation of secondary hemoastsis (i.e.,
thrombosis) in animal models of liver IRI.
This may or may not be correct, but the citation is out of context as the first and last
parts are clearly separated by a comma and are unrelated ideas. Actually, the flow of
ideas is as follows:
“We have described extensive blebbing of SEC plasma membrane during the first
20min of post-ischemic IR (10) [note, this statement is entirely correct as illustrated in
the cited reference], [also please note the comma, used here to indicate a change of
idea] leading us to conceive the hypothesis that MPs originating from the perturbed
plasma membranes of SECs contribute to the microvascular inflammatory and pro-
thrombotic responses in hepatic IRI”.
We believe it unecessary to cite a reference to support an idea/proposition (if it was
known, why do the experiment?). Nonetheless, to support an interpretation such as
made by the reviewer that this may have been proven already (ie. that prothrombotic
responses contribute to microvascular occlusion in IRI), we have changed the wording
at the end of the sentence to: “…inflammatory and platelet-activating responses…”(pg
7). We hope this is less controversial as the role of platelets was introduced earlier with
citation (reference 10).
3) Materials and methods: Did the animals receive analgesia in addition to the
ketamine/ xylazine mixture?
Yes, indeed. For experiments to conform to the high standards mandated
internationally (see Ethics statement) and in Australia, this is a legal requirement. In
addition to ketamine and xylazine, low dose temgesic was administered for analgesia
at wound closure (doses titrated to comfort without compromising the animals’
recovery). A note to this effect has been added at beginning of pg 8 (Materials and
Methods).
4) The primary hepatocyte isolation and culture should be presented in more detail. A
successful hepatocyte isolation depends on a lot of factors, such as the perfusate
temperature, the flow rate, etc. In addition, hepatocytes cultures are very sensitive to
the amount of, e.g., serum and glucocorticoids in the culture medium.
The perfusate temperature: 37oC; flow rate: 8 mL/min. Williams E media was
supplemented with only 10% heat-inactivated fetal bovine serum as experiments were
only short-term. These details have been included in the revised text (pg 9).
5) Why is the hypoxic chamber flushed with 95% O2 to simulate reperfusion?
Considering that mitochondrial superoxide production is directly proportional to the O2
concentration (PMID 14561818), the hyperoxia per se could already be toxic.
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We performed control hepatocyte cultures where cells were exposed to 21% O2
initially, then flushed identically to simulate reperfusion with ‘normoxia’ (this is correctly
stipulated on pg 17, line 10 but incorrectly [we apologise] stated in the Methods pg 9)
as the test cells. A correction has been made to the revised Materials and Methods (pg
9).
6) How specific is the PS ELISA for MPs? I can imagine that PS is also expressed on
circulating apoptotic cell remnants, which would also be detected by the ELISA.
The reviewer is correct: PS is everted on apoptotic remnants as well as
exosomes/MPs. For this reason, we used a gated FACS strategy (see Methods pg 9)
to exclude detection of larger particles (which can include apoptotic remnants) when
we used cell-protein-specific fluorescent antibodies. We have added a comment in the
revised Results (pg 12) and Discussion (pg 21) sections to indicate this limitation of
using annexin V ELISA for quantitation of “total circulating microparticles”.
7) 2,7-dichlororofluorescein diacetate (DCFDA) is not a probe for oxidative stress
measurements, but is a compound that becomes fluorescent immediately after
cytosolic deacetylation, irrespective of oxidative events. Please verify whether DCFDA
was used, or that it’s just incorrect use of nomenclature and the correct probe 2,7-
dichlororodihydofluorescein diacetate (DCFH2-DA) was used instead.
Reviewer 1 is correct. We used the dihydro-derivative to detect oxidative stress. The
relevant parts of the text have been amended (pg 12) – thanks for picking this up.
In addition, please include the solvent in which the assay was performed (culture
medium or PBS?) and the type and final concentration of the solvent that was used to
dissolve the probe. These parameters directly influence the outcome of the assay.
These are primary cell cultures so the assay was performed using William’s E media.
The solvent for the probe DCFH2-DA was PBS at a final concentration of 10M (thus,
the final concentration of solvent is negligible in media used for primary cell culture)(pg
12).
8) Were neutrophils enriched from the isolated leukocytes for the transmigration
assays or was the complete non-parenchymal cell fraction used? If needed, please
modify the title of the transmigration assay accordingly.
Neutrophils were enriched, as inferred by passage of the preparation through a Ficoll-
Paque gradient (pg 11). We have stated this more clearly in the revised manuscript.
The title of the transmigration assay has been modified.
9) The circulating HA that is measured as a marker for SEC injury could also be
derived from the glycocalyx on the endothelial surface and therefore does not solely
reflect endothelial cell injury.
It is likely derived from the endothelial surface, reflecting endothelial cell activation
and/or injury (the 2 facets are inseparable experimentally). We have made a note to
clarify this ambiguity in the amended Results, paragraph 1.
10) Results: “The time discrepancy … hepatic injury in IRI”. The claim is not fully in line
with the fact that MP release peaks after 24 h of reperfusion, at which point the peak in
hepatocellular injury has already passed (6 h in most IRI models).
We meant the discrepancy between the early rise in MP release during the first 30 min
of reperfusion, not at 24 hr. We have now clarified this in the text by the wording: “…
time discrepancy between early increases in MP and ALT levels…”(pg 12).
11) “To characterize the MPs that … (Supplementary Table 1)”. This sentence is
unclear and should be rephrased.
Agree – thanks. It has now been re-written in 2 sentences to explain the gating and
fluorescent-labelled antibody strategies separately (pg 13, paragraph 2).
12)  CD62p is not only found on platelets, but also on (activated) endothelial cells.
Please correct throughout the manuscript (e.g., Figure 2D).
We thank the reviewer for drawing that to our attention. Appropriate corrections have
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been made throughout the manuscript (eg. pg 13), including in the figure legend to
Figure 2D (pg 27).
13) ASGPR (Figure 1D) is not included in the materials and methods section.
We have added ASGPR to Materials and Methods section (Western blot analysis, pg
11 and to Supplementary Methods).
14) How does the fact that MPs contain bioactive lipids lead to the hypothesis that they
are directly cytotoxic to hepatocytes? There are a lot of cell types that have pro-
inflammatory potential that are absolutely harmless in a hepatocyte co-culture.
MPs are not cell types – there is a fundamental difference as clearly explained in the
Introduction to our paper. Further, we did carefully express our wording as (pg 14,
paragraph 2):
“Because of their potential relevance to…”, and later (pg 15): “Because of their
bioactive lipid content, MPs could also be directly cytopathic…”, so we have not
dogmatically drawn a link between the measured bioactive lipids and hepatocyte
cytotoxicity as inferred by Reviewer 1’s criticism.
However, in order to soften the link between bioactive lipids and cytotoxicity as a
unique connecting idea, we have added the additional phrase (pg 15, paragraph 2):
“bioactive lipid content, potentially reactive oxygen intermediates and other pro-
oxidants, MPs could also be directly cytopathic to hepatocytes.” Since it is evident by
the results of our experiments, which seem to be highly original in the field, that
circulating MPs are indeed cytopathic to hepatocytes, we do not really understand this
reviewer’s concerns.
15) Were control cells incubated for 30 min in PBS in the oxidative stress
measurement experiments (Fig. 3B)? In our experience, this is very poorly tolerated by
primary hepatocytes.
The reviewer may have misunderstood our experimental design. To clarify, the MPs
were added in a tiny volume of PBS (200 microL) to hepatocytes cultured in William’s
E, as stated in Methods. As indicated by the Reviewer, it would be a flawed design to
do test cultures in one (ie. no) media (namely, PBS) and controls in another (William’s
E media). We think this is such a fundamental tenant of experimental design but to
ensure clarity, we have amended the text (pg 15, line 20).
16)  “these findings imply … to IRI (1-6)”. How does the expression of adhesion
molecules relate to the different chemoattractants that are expressed during IRI?
We agree this is poorly worded and is now re-stated (p17, paragraph 1): “Thus, the
profile of pro-inflammatory adhesion molecules borne on MPs differs with perfusion
time. Further, it recapitulates the suite of different adhesion molecules known to be
expressed in livers subject to IRI (1-6).”
17). Doesn’t Ca2+ chelation with EGTA lead to immediate dissociation of the
monolayer? (Fig. 4C).
No. Otherwise, we could not have performed this experiment. These were only short-
term cultures.
18) SP600125 is missing from the materials and methods section.
SP600125 has now been included in the revised Materials and Methods section (pg 9).
19) Discussion: The discussion is relatively superficial and reiterates a lot of the
experimental findings without speculating on the underlying mechanisms.
While we respect the reviewer’s opinion, we have tried to establish likely mechanisms
by interpreting our novel data in light of what is already known. This is a standard
approach, as recommended by ‘Instructions to Authors’. We do not want to over-
extrapolate or speculate (to use the reviewer’s word) too far, but have re-written the
Discussion section in an attempt to clarify the wording of our ideas.
20) Several critical experimental findings remain underexposed, such as: 1. How MPs
most likely exert their chemotactic effects and how NAC pretreatment revokes this
potential.
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We agree this is fundamental and could be discussed more clearly; we have
completely re-written paragraph 2, pg 22 and paragraph 1, pg 23 accordingly, including
a comment about the implications of NAC pre-treatment preventing MP formation in
vivo and reducing oxidant stress in hepatocytes in vitro. We have not specifically
shown that NAC pre-treatment revokes chemotactic effects, so this is not discussed.
21) Discussion 2. How the shift in the bioactive lipid profile of MPs relates to the
cellular origin of these MPs and how this plays out with respect to IRI.
This is a good point that is more clearly addressed in the revised Discussion (pg 22,
paragraph 2). In particular, we have added the sentence:
“The nature of our studies in an intact organ in vivo does not allow clarification of why
MP lipid composition changes with post-ischemic time, other than to note that AA and
F2-isoprostanes which were detected later may be more abundant in platelets and
macrophages than in hepatocytes.”
Reviewer #2: PONE-D-14-14438
This is a Herculean effort to investigate the role of microparticles released during
hepatic ischemic reperfusion injury and to characterize the effect of diannexin on its
production and function. It is a comprehensive study utilizing mouse model to illustrate
the physiological significance of its release, as well as primary hepatocytes to gain
mechanistic insights. Experimental design successfully encapsulated a multi-layered
investigation that explored both the upstream conditions leading to their release as well
as the functional outcomes. The key finding of this work is the groundbreaking
characterization that different cell origins (e.g. SEC platelets, macrophages) for the
microparticles were released during different stages of IRI. They also convincingly
demonstrated that these microparticles carry bioactive components to trigger
inflammatory responses and neutrophil transmigration. The authors capped off this
illustrious work with the hepatoprotective function of diannexin in mitigating the
proinflammatory and pro-oxidant properties of microparticles during IRI. Overall, this is
a very high quality piece of research work that adds great value to our understanding
of microparticles during IRI and the therapeutic potential of their inhibition.
We greatly appreciate these insights from Reviewer 2. It has been an opus of work
conducted in a very small lab, over several years, in pursuit of a more complete story
rather than the simple documentation of a phenomena (or description of an unlikely
“single pathway”) in hepatic IRI. Getting the work published has been as arduous as
the research and it is refreshing to read such a positive appreciation – heartfelt thanks
from the authors!
Some minor comments are as follows:
1. On page 10, in the method description for neutrophil transmigration assay, the
details for the pre-treatment of MP with NAC or diannexin should be elaborated. At
which stage of the process was NAC and diannexin added in? Were these agents
methodically removed through washing, prior to the transwell migration assay? Since
these agents may cross the transwell, their presence during the transwell assay may
confound the findings as they may cross the membrane and exert a direct effect on the
neutrophils.
These important details of experimental design have been now been clarified in the
Materials and Methods Section (pg 11).
2. The images in Figure 2C do not clearly distinguish between the ones treated MP-
alone and those with hypertonic sucrose. Figure could be annotated to help pinpoint
the differences more clearly.
These helpful points have been attended to in the revised Figure 2C (second row of
images now carry the label ‘Sucrose 0.45M’ on the far left of the figure) and revised
figure legend.
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3. Figure 6C, the b-actin bands are very faint and may not be too accurate for
densitometric analysis.
Western blots using the same samples have been repeated and densitometric analysis
performed to confirm the findings. Clearer and more apparent b-actin bands are now
included in the revised Figure 6C.
Additional Information:
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Financial Disclosure
Please describe all sources of funding
that have supported your work. A
complete funding statement should do the
following:
Include grant numbers and the URLs of
any funder's website. Use the full name,
not acronyms, of funding institutions, and
use initials to identify authors who
received the funding.
Describe the role of any sponsors or
funders in the study design, data
collection and analysis, decision to
publish, or preparation of the manuscript.
If they had no role in any of the above,
include this sentence at the end of your
statement: "The funders had no role in
study design, data collection and analysis,
decision to publish, or preparation of the
manuscript."
If the study was unfunded, provide a
statement that clearly indicates this, for
example: "The author(s) received no
specific funding for this work."
* typeset
This work was supported by the Australian National Health and Medical Research
Council’s (NHMRC) project grants #1008958, #585414 and the Australian Capital
Territory’s Health and Medical Research seed grant 2009-2010.
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21
st
 June 2014 
Professor Thiruma V. Arumugam, PhD 
Academic Editor 
PLOS ONE  
 
Dear Professor Arumugam, 
 
Re: PONE-D-14-14438 
Microparticles mediate hepatic ischemia-reperfusion injury and are the targets of Diannexin 
(ASP8597) 
 
Thank you for your letter dated 9
th
 May 2014. We are grateful that you consider our 
manuscript will likely be suitable for publication, and we are now pleased to submit a revised 
version addressing all the points stipulated. We also enclose a ‘point-by-point’ response to 
the two reviewers’ comments. 
 
There are no changes to our financial disclosures. Unfortunately one of the authors, Emeritus 
Professor Anthony Allison passed away in February 2014. We understand he was no longer a 
financial employee of Alavita Inc 2 years earlier (ie. January 2012) so clearly, there was no 
impression of potential conflict of interest. We have noted the late Emeritus Professor 
Allison’s passing by indicating ‘deceased’ after his name in the author list and by a footnote; 
we would be grateful if you would allow us to insert a brief tribute to his memory (1 sentence 
dedication) in the front pages of the manuscript. 
 
We have uploaded a clean revised manuscript as our 'Manuscript' file, and a marked-up copy 
of the changes made (changes underlined) from the previous article file as a 'Revised 
Manuscript with Track Changes' file.  
 
Thank you for considering this revised version for publication in PLOS ONE. 
 
 
Yours sincerely,  
 
Narci Teoh and Geoff Farrell,  
on behalf of all the authors 
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Point-by-Point Responses (in italics) 
JOURNAL REQUIREMENTS 
 
When submitting your revision, we need you to address these additional requirements. 
 
1. We noticed that you did not deposit your data to a publicly available database, or include it 
in the submission form. All PLOS journals now require raw data underlying the findings 
described in the manuscript to be freely available to other researchers, either in a public 
repository, or in the manuscript itself. Should your paper be accepted for publication, you 
must state exactly where your data is deposited, and provide accession numbers or DOIs.  
 
Thank you for the reminder. Our data in the revised manuscript has been submitted to the 
Australian National University’s Research Data Repository called ‘ANU Research’ and is 
now freely accessible by interested members of the public. ANU Research can be found here 
at https://www.anu.edu.au/research/access/index.php. 
Email confirmation from ‘ANU Research’ (data repository coordinator: Katy Najafi) has 
been appended in the submission as evidence. 
 
 
 
2. Please amend either the title on the online submission form (via Edit Submission) or the 
title in the manuscript so that they are identical. 
 
This has been amended online to reflect the title in the manuscript:  
“Microparticles mediate hepatic ischemia-reperfusion injury and are the targets of 
Diannexin (ASP8597)” 
 
3. Please include your tables as part of your main manuscript and remove the individual files. 
Please note that supplementary tables (should remain/ be uploaded) as separate "supporting 
information" files. 
 
Table 1 is now part of the main manuscript (pg 32). The supplementary tables have remained 
as separate “supporting information” files. 
 
4. Thank you for stating the following in the Competing Interests section: "The authors have 
declared that no competing interests exist”. We note that one of the authors is employed by a 
commercial company ‘Alavita Inc’. 
 
We wish to clarify that this declaration still holds and that there are no changes to our 
financial disclosures. Emeritus Professor Anthony Allison sadly passed away in February 
2014. He ceased to be an employee of Alavita Inc 2 years prior, due to ill health (ie. was no 
longer financially paid by Alavita Inc from January 2012) so clearly, there was no 
impression of potential conflict of interest at the time when the Diannexin experiments were 
performed, and when the manuscript was written and submitted in 2014. We have noted the 
late Professor Allison’s passing by indicating ‘deceased’ after his name in the author list. 
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REVIEWERS’ COMMENTS 
 
We thank both reviewers for their general comments and their responses to the journal’s 
questions. 
 
We note Reviewer 1’s response to question 4 as follows: 
 
4. Is the manuscript presented in an intelligible fashion and written in standard English? 
Reviewer #1: No 
Reviewer #2: Yes 
 
Reviewer 1 has raised concerns about clarity and flow of ideas in the article. We agree there 
are several experimental approaches that analyse the subject (eg. formation and 
pathogenicity of microparticles [MPs] in liver ischemia-reperfusion injury [IRI]) in 
considerable detail, as acknowledged by Reviewer 2’s general comments. This will place a 
challenge for the reader unless our rationale for each approach is clearly stated.  
 
With the assistance of specific comments made by the reviewers, we have carefully re-written 
much of the manuscript to improve its readability. We thank the reviewers for bringing this to 
our attention and trust the paper now achieves the high standards sought by PLOS ONE. 
 
5. Reviewer Comments to the Author 
 
Reviewer #1: PONE-D-14-14438 
The authors have used a murine model of hepatic ischemia/reperfusion injury (IRI) to 
characterize the cellular source and biological effects of microparticles (MPs) in post-
ischemic liver inflammation. It is shown that MPs originate during early reperfusion from 
nearly all IRI-pertinent cell types, are directly toxic to hepatocytes, are leukocyte 
chemoattractants, and have the ability to activate platelets. The release as well as the pro-
inflammatory effects of MPs could be attenuated by administering the Annexin V homodimer 
Diannexin, which reportedly does so by shielding phosphatidylserine (PS) residues exposed 
on the MP outer membrane leaflet.  
 
Strength: 
The major strength of the manuscript is that it sheds light on a completely novel 
pathophysiological aspect of hepatic IRI. The characterization of MPs is very thorough and 
provides for an interesting therapeutic avenue. The work performed falls within the high level 
of research that is expected from the Farrell and Teoh group.  
Thank you for these very positive and encouraging comments. 
 
Weakness:  
The most important drawback of the manuscript is that the rationale for some of the 
performed experiments is not always clear, which makes the paper difficult to follow at 
times. A large variety of parameters have been measured without placing the (often very 
interesting) findings in context of the rest of the data. The manuscript would benefit from a 
more comprehensive and accessible/focused presentation of data and a more in-depth 
discussion.  
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The authors have noted these constructive comments. We acknowledge “clunky” areas in the 
manuscript where we rapidly switched ‘gears’ ie. concepts or experimental platforms, for 
example, from in vivo to in vitro systems, or from injury to inflammation. With the reviewer 
1’s help in identifying some of these areas, we have made very substantive changes to 
improve the clarity and logical flow of the article. With these comments in mind, we have 
given considerable thought to an extensive revision of the discussion; these amendments are 
underlined in the revised version. 
 
Minor comments: 
 
Introduction. Kindly note: we have changed the bullet points to numbers for ease of reference 
to our responses. 
 
1) “these adhere to SECs … factor- (TNF)”. The leukocyte recruitment paradigm differs 
between the sinusoids (SECs) and post-sinusoidal venules, especially with respect to 
endothelial leukocyte receptors. Please verify whether the mentioned adhesion molecules are 
indeed expressed on SECs and if they are relevant for liver IRI/sterile inflammation (see, e.g., 
PMIDs 22064428, 22982943).  
We have checked the 2 recent references cited and are very familiar with references 1 - 6 in 
the manuscript (one by us) which we cite in favour of this point. Yes, the stated adhesion 
molecules are expressed on SECs and are relevant to liver sterile inflammation and IRI.  
 
2) “We have described … pro-thrombotic responses in hepatic IRI”. To our knowledge, very 
few papers have clearly shown activation of secondary hemoastsis (i.e., thrombosis) in 
animal models of liver IRI.  
 
This may or may not be correct, but the citation is out of context as the first and last parts are 
clearly separated by a comma and are unrelated ideas. Actually, the flow of ideas is as 
follows:  
“We have described extensive blebbing of SEC plasma membrane during the first 20min of 
post-ischemic IR (10) [note, this statement is entirely correct as illustrated in the cited 
reference], [also please note the comma, used here to indicate a change of idea] leading us to 
conceive the hypothesis that MPs originating from the perturbed plasma membranes of SECs 
contribute to the microvascular inflammatory and pro-thrombotic responses in hepatic IRI”.  
 
We believe it unecessary to cite a reference to support an idea/proposition (if it was known, 
why do the experiment?). Nonetheless, to support an interpretation such as made by the 
reviewer that this may have been proven already (ie. that prothrombotic responses contribute 
to microvascular occlusion in IRI), we have changed the wording at the end of the sentence 
to: “…inflammatory and platelet-activating responses…”(pg 7). We hope this is less 
controversial as the role of platelets was introduced earlier with citation (reference 10). 
 
 
3) Materials and methods: Did the animals receive analgesia in addition to the ketamine/ 
xylazine mixture?  
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Yes, indeed. For experiments to conform to the high standards mandated internationally (see 
Ethics statement) and in Australia, this is a legal requirement. In addition to ketamine and 
xylazine, low dose temgesic was administered for analgesia at wound closure (doses titrated 
to comfort without compromising the animals’ recovery). A note to this effect has been added 
at beginning of pg 8 (Materials and Methods). 
 
 
4) The primary hepatocyte isolation and culture should be presented in more detail. A 
successful hepatocyte isolation depends on a lot of factors, such as the perfusate temperature, 
the flow rate, etc. In addition, hepatocytes cultures are very sensitive to the amount of, e.g., 
serum and glucocorticoids in the culture medium.  
 
The perfusate temperature: 37
o
C; flow rate: 8 mL/min. Williams E media was supplemented 
with only 10% heat-inactivated fetal bovine serum as experiments were only short-term. 
These details have been included in the revised text (pg 9). 
 
5) Why is the hypoxic chamber flushed with 95% O2 to simulate reperfusion? Considering 
that mitochondrial superoxide production is directly proportional to the O2 concentration 
(PMID 14561818), the hyperoxia per se could already be toxic.  
 
We performed control hepatocyte cultures where cells were exposed to 21% O2 initially, then 
flushed identically to simulate reperfusion with ‘normoxia’ (this is correctly stipulated on pg 
17, line 10 but incorrectly [we apologise] stated in the Methods pg 9) as the test cells. A 
correction has been made to the revised Materials and Methods (pg 9). 
 
 
6) How specific is the PS ELISA for MPs? I can imagine that PS is also expressed on 
circulating apoptotic cell remnants, which would also be detected by the ELISA.  
 
The reviewer is correct: PS is everted on apoptotic remnants as well as exosomes/MPs. For 
this reason, we used a gated FACS strategy (see Methods pg 9) to exclude detection of larger 
particles (which can include apoptotic remnants) when we used cell-protein-specific 
fluorescent antibodies. We have added a comment in the revised Results (pg 12) and 
Discussion (pg 21) sections to indicate this limitation of using annexin V ELISA for 
quantitation of “total circulating microparticles”.  
 
 
7) 2,7-dichlororofluorescein diacetate (DCFDA) is not a probe for oxidative stress 
measurements, but is a compound that becomes fluorescent immediately after cytosolic 
deacetylation, irrespective of oxidative events. Please verify whether DCFDA was used, or 
that it’s just incorrect use of nomenclature and the correct probe 2,7-
dichlororodihydofluorescein diacetate (DCFH2-DA) was used instead.  
 
Reviewer 1 is correct. We used the dihydro-derivative to detect oxidative stress. The relevant 
parts of the text have been amended (pg 12) – thanks for picking this up. 
 
In addition, please include the solvent in which the assay was performed (culture medium or 
PBS?) and the type and final concentration of the solvent that was used to dissolve the probe. 
These parameters directly influence the outcome of the assay.  
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These are primary cell cultures so the assay was performed using William’s E media. The 
solvent for the probe DCFH2-DA was PBS at a final concentration of 10M (thus, the final 
concentration of solvent is negligible in media used for primary cell culture)(pg 12). 
 
8) Were neutrophils enriched from the isolated leukocytes for the transmigration assays or 
was the complete non-parenchymal cell fraction used? If needed, please modify the title of 
the transmigration assay accordingly.  
Neutrophils were enriched, as inferred by passage of the preparation through a Ficoll-Paque 
gradient (pg 11). We have stated this more clearly in the revised manuscript. The title of the 
transmigration assay has been modified.  
 
9) The circulating HA that is measured as a marker for SEC injury could also be derived from 
the glycocalyx on the endothelial surface and therefore does not solely reflect endothelial cell 
injury.  
It is likely derived from the endothelial surface, reflecting endothelial cell activation and/or 
injury (the 2 facets are inseparable experimentally). We have made a note to clarify this 
ambiguity in the amended Results, paragraph 1. 
 
10) Results: “The time discrepancy … hepatic injury in IRI”. The claim is not fully in line 
with the fact that MP release peaks after 24 h of reperfusion, at which point the peak in 
hepatocellular injury has already passed (6 h in most IRI models).  
We meant the discrepancy between the early rise in MP release during the first 30 min of 
reperfusion, not at 24 hr. We have now clarified this in the text by the wording: “… time 
discrepancy between early increases in MP and ALT levels…”(pg 12). 
 
11) “To characterize the MPs that … (Supplementary Table 1)”. This sentence is unclear and 
should be rephrased.  
Agree – thanks. It has now been re-written in 2 sentences to explain the gating and 
fluorescent-labelled antibody strategies separately (pg 13, paragraph 2). 
 
12)  CD62p is not only found on platelets, but also on (activated) endothelial cells. Please 
correct throughout the manuscript (e.g., Figure 2D).  
We thank the reviewer for drawing that to our attention. Appropriate corrections have been 
made throughout the manuscript (eg. pg 13), including in the figure legend to Figure 2D (pg 
27). 
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13) ASGPR (Figure 1D) is not included in the materials and methods section.  
We have added ASGPR to Materials and Methods section (Western blot analysis, pg 11 and 
to Supplementary Methods). 
 
14) How does the fact that MPs contain bioactive lipids lead to the hypothesis that they are 
directly cytotoxic to hepatocytes? There are a lot of cell types that have pro-inflammatory 
potential that are absolutely harmless in a hepatocyte co-culture.  
MPs are not cell types – there is a fundamental difference as clearly explained in the 
Introduction to our paper. Further, we did carefully express our wording as (pg 14, 
paragraph 2):  
“Because of their potential relevance to…”, and later (pg 15): “Because of their bioactive 
lipid content, MPs could also be directly cytopathic…”, so we have not dogmatically drawn a 
link between the measured bioactive lipids and hepatocyte cytotoxicity as inferred by 
Reviewer 1’s criticism.  
However, in order to soften the link between bioactive lipids and cytotoxicity as a unique 
connecting idea, we have added the additional phrase (pg 15, paragraph 2): “bioactive lipid 
content, potentially reactive oxygen intermediates and other pro-oxidants, MPs could also be 
directly cytopathic to hepatocytes.” Since it is evident by the results of our experiments, 
which seem to be highly original in the field, that circulating MPs are indeed cytopathic to 
hepatocytes, we do not really understand this reviewer’s concerns.  
 
15) Were control cells incubated for 30 min in PBS in the oxidative stress measurement 
experiments (Fig. 3B)? In our experience, this is very poorly tolerated by primary 
hepatocytes.  
The reviewer may have misunderstood our experimental design. To clarify, the MPs were 
added in a tiny volume of PBS (200 microL) to hepatocytes cultured in William’s E, as stated 
in Methods. As indicated by the Reviewer, it would be a flawed design to do test cultures in 
one (ie. no) media (namely, PBS) and controls in another (William’s E media). We think this 
is such a fundamental tenant of experimental design but to ensure clarity, we have amended 
the text (pg 15, line 20). 
 
16)  “these findings imply … to IRI (1-6)”. How does the expression of adhesion molecules 
relate to the different chemoattractants that are expressed during IRI?  
We agree this is poorly worded and is now re-stated (p17, paragraph 1): “Thus, the profile 
of pro-inflammatory adhesion molecules borne on MPs differs with perfusion time. Further, 
it recapitulates the suite of different adhesion molecules known to be expressed in livers 
subject to IRI (1-6).” 
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17). Doesn’t Ca2+ chelation with EGTA lead to immediate dissociation of the monolayer? 
(Fig. 4C).  
No. Otherwise, we could not have performed this experiment. These were only short-term 
cultures. 
18) SP600125 is missing from the materials and methods section.  
SP600125 has now been included in the revised Materials and Methods section (pg 9). 
 
19) Discussion: The discussion is relatively superficial and reiterates a lot of the experimental 
findings without speculating on the underlying mechanisms.  
While we respect the reviewer’s opinion, we have tried to establish likely mechanisms by 
interpreting our novel data in light of what is already known. This is a standard approach, as 
recommended by ‘Instructions to Authors’. We do not want to over-extrapolate or speculate 
(to use the reviewer’s word) too far, but have re-written the Discussion section in an attempt 
to clarify the wording of our ideas. 
 
20) Several critical experimental findings remain underexposed, such as: 1. How MPs most 
likely exert their chemotactic effects and how NAC pretreatment revokes this potential.  
 
We agree this is fundamental and could be discussed more clearly; we have completely re-
written paragraph 2, pg 22 and paragraph 1, pg 23 accordingly, including a comment about 
the implications of NAC pre-treatment preventing MP formation in vivo and reducing oxidant 
stress in hepatocytes in vitro. We have not specifically shown that NAC pre-treatment revokes 
chemotactic effects, so this is not discussed. 
 
 
21) Discussion 2. How the shift in the bioactive lipid profile of MPs relates to the cellular 
origin of these MPs and how this plays out with respect to IRI.  
 
This is a good point that is more clearly addressed in the revised Discussion (pg 22, 
paragraph 2). In particular, we have added the sentence:  
“The nature of our studies in an intact organ in vivo does not allow clarification of why MP 
lipid composition changes with post-ischemic time, other than to note that AA and F2-
isoprostanes which were detected later may be more abundant in platelets and macrophages 
than in hepatocytes.” 
 
 
 
Reviewer #2: PONE-D-14-14438 
This is a Herculean effort to investigate the role of microparticles released during hepatic 
ischemic reperfusion injury and to characterize the effect of diannexin on its production and 
function. It is a comprehensive study utilizing mouse model to illustrate the physiological 
significance of its release, as well as primary hepatocytes to gain mechanistic insights. 
Experimental design successfully encapsulated a multi-layered investigation that explored 
both the upstream conditions leading to their release as well as the functional outcomes. The 
key finding of this work is the groundbreaking characterization that different cell origins (e.g. 
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SEC platelets, macrophages) for the microparticles were released during different stages of 
IRI. They also convincingly demonstrated that these microparticles carry bioactive 
components to trigger inflammatory responses and neutrophil transmigration. The authors 
capped off this illustrious work with the hepatoprotective function of diannexin in mitigating 
the proinflammatory and pro-oxidant properties of microparticles during IRI. Overall, this is 
a very high quality piece of research work that adds great value to our understanding of 
microparticles during IRI and the therapeutic potential of their inhibition.  
 
We greatly appreciate these insights from Reviewer 2. It has been an opus of work conducted 
in a very small lab, over several years, in pursuit of a more complete story rather than the 
simple documentation of a phenomena (or description of an unlikely “single pathway”) in 
hepatic IRI. Getting the work published has been as arduous as the research and it is 
refreshing to read such a positive appreciation – heartfelt thanks from the authors! 
 
 
Some minor comments are as follows: 
1. On page 10, in the method description for neutrophil transmigration assay, the details for 
the pre-treatment of MP with NAC or diannexin should be elaborated. At which stage of the 
process was NAC and diannexin added in? Were these agents methodically removed through 
washing, prior to the transwell migration assay? Since these agents may cross the transwell, 
their presence during the transwell assay may confound the findings as they may cross the 
membrane and exert a direct effect on the neutrophils.  
 
These important details of experimental design have been now been clarified in the Materials 
and Methods Section (pg 11). 
 
 
2. The images in Figure 2C do not clearly distinguish between the ones treated MP-alone and 
those with hypertonic sucrose. Figure could be annotated to help pinpoint the differences 
more clearly.  
 
These helpful points have been attended to in the revised Figure 2C (second row of images 
now carry the label ‘Sucrose 0.45M’ on the far left of the figure) and revised figure legend. 
 
 
3. Figure 6C, the b-actin bands are very faint and may not be too accurate for densitometric 
analysis.  
 
Western blots using the same samples have been repeated and densitometric analysis 
performed to confirm the findings. Clearer and more apparent b-actin bands are now 
included in the revised Figure 6C. 
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ABBREVIATIONS 
 
AA  arachidonic acid 
ASGPR asialoglycoprotein receptor 
COX-2  cyclooxygenase-2 
DCFH2-DA 6-carboxy-2',7'-dichlorodihydrofluorescein diacetate 
EGTA  ethylene glycol tetra-acetic acid 
E-selectin endothelial-selectin 
GSH  glutathione 
GSSG  oxidized reduced glutathione 
HA  hyaluronic acid 
HR  hypoxia-reoxygenation 
ICAM-1 intercellular adhesion molecule 1 
IRI  ischemia reperfusion injury 
JNK  c-jun n-terminal kinase 
MPs  microparticles 
MPT  mitochondrial permeability transition 
MTT  (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
NAC  N-acetylcysteine 
PKC-δ  protein kinase delta 
PS  phosphatidylserine 
P-selectin platelet-selectin 
TMRM tetramethylrhodamine methyl ester 
VCAM-1 vascular cell adhesion molecule 1 
VE-cadherin vascular endothelial-cadherin  
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ABSTRACT  
 
BACKGROUND & AIMS: Ischemia–reperfusion injury (IRI) can cause hepatic failure 
after liver surgery or transplantation. IRI causes oxidative stress, which injures sinusoidal 
endothelial cells (SECs), leading to recruitment and activation of Kupffer cells and platelets 
(by unknown processes) and microcirculatory impairment. We investigated whether injured 
SECs and other cell types release microparticles (small fragments shed from outer leaf of 
the plasma membrane) during post-ischemic reperfusion, and whether such microparticles 
have pro-inflammatory, platelet-activating and pro-injurious effects that could contribute to 
IRI pathogenesis.  
METHODS: C57BL6 mice underwent 60 min of partial hepatic ischemia followed by 15 
min–24 hrs of reperfusion. We collected blood and liver samples, isolated and measured 
circulating microparticles, and determined protein and lipid content. To establish 
mechanism for production of microparticles, we subjected murine primary hepatocytes to 
hypoxia-reoxygenation. Finally, because microparticles express everted phosphatidylserine 
residues that are the target of annexin V, we analyzed the effects of an annexin V-
homodimer (Diannexin or ASP8597) on post-ischemia microparticle production and 
function. 
RESULTS: Microparticles were detected in the circulation 15–30 min after post-ischemic 
reperfusion, and contained markers of SECs, platelets, natural killer T cells, and CD8
+ 
cells; 
4 hrs later, they contained markers of macrophages. Microparticles also contained F2-
isoprostanes, indicating oxidative damage to membrane lipids. Injection of mice with tumor 
necrosis factor-increased microparticle formation, whereas Diannexin substantially 
reduced microparticle release and prevented IRI. Hypoxia-re-oxygenation generated 
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microparticles from primary hepatocytes by processes that involved oxidative stress and 
ionic calcium. Exposing cultured hepatocytes to preparations of microparticles isolated from 
the circulation during IRI caused injury involving mitochondrial membrane permeability 
transition. Microparticles also activated platelets and induced neutrophil migration in vitro. 
The inflammatory properties of microparticles involved activation of NF-B and JNK, and 
increased expression of E-selectin, P-selectin, ICAM-1, and VCAM-1. All these processes 
were blocked by coating microparticles with Diannexin.   
CONCLUSIONS: Following post-ischemic reperfusion of mouse liver, microparticles 
(mainly derived from SECs, platelets, and lymphocytes) circulate and can be taken up by 
hepatocytes, where they activate signaling pathways that mediate inflammation and 
hepatocyte injury. Microparticles also activate neutrophil recruitment and platelet activation 
directly. Diannexin prevents microparticle formation and subsequent inflammation. 
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INTRODUCTION 
Hepatic ischemia-reperfusion injury (IRI) remains an important complication of 
liver surgery and transplantation (1,2). In the early phase (first 2hr), hepatic damage is 
caused by oxidative stress, generated by Kupffer cells (KCs) with damage to sinusoidal 
endothelial cells (SECs) (1-6). The late phase (6-24hr) is mediated by hepatic recruitment of 
leukocytes and macrophages. These adhere to SECs that express adhesion molecules (E-
selectin, P-selectin, ICAM-1, VCAM-1) and secrete chemokines (5-8) in response to 
hypoxia, oxidative stress, and tumor necrosis factor- (TNF) (8). Platelets are essential for 
hepatic IRI (9); platelet clumps adhere to damaged SECs during the first 20 min of post-
ischemic reperfusion (10). The factors linking early SEC injury to inflammatory cell 
recruitment and platelet activation, with resultant microcirculatory impairment and 
hepatocyte injury have not been fully clarified. 
 
Microparticles (MPs) are small (0.1–1.0m) fragments shed from blebbing of the 
outer leaf of plasma membranes of activated cells, such as platelets, macrophages, 
endothelial cells, lymphocytes, and hepatocytes, or from cells undergoing apoptosis (11,12). 
They are important in promoting inflammation and thrombotic responses following vascular 
dysfunction (11-16). MPs harbour cell membrane proteins (used to identify their cellular 
origin) which also contain biologically active lipids. On their surface, MPs exhibit 
negatively charged phospholipids, chiefly phosphatidylserine (PS) which accounts for their 
pro-coagulant and pro-inflammatory properties (11-16). Levels of circulating MPs increase 
in acute coronary ischemia, myocardial infarction and pre-eclampsia, likely contributing to 
the associated leukocyte and platelet adhesion and obstruction of microvascular blood flow 
(11-13).  
                                                                                                                      
    
7
Involvement of MPs in the pathogenesis of liver disease has been suggested in 
cirrhosis and hepatitis (17-19) but has not been reported so far in hepatic IRI. We have 
described extensive blebbing of SEC plasma membranes during the first 20min of post-
IR(10), leading us to conceive the hypothesis that MPs originating from perturbed plasma 
membranes of SECs contribute to the microvascular inflammatory and platelet activating 
responses in hepatic IRI. In the present work, we conducted experiments in a well-validated 
murine model of partial hepatic IRI (8,10) to demonstrate time-dependent production of 
MPs in liver IRI, and to characterize their cellular derivation and lipid composition. We then 
determined the pathogenic effects of MPs, specifically their ability: (i) to cause hepatocyte 
injury directly, (ii) to activate platelets, (iii) to promote neutrophil recruitment, and (iv) to 
generate pro-inflammatory mediators, reactive oxygen species (ROS) and mitochondrial 
permeability transition (MPT)(7). 
To pursue these aims we used a variety of complementary in vitro and in vivo 
approaches. We subjected primary hepatocytes to hypoxia-reoxygenation (HR) and showed 
that mitochondrial injury, activation of the c-jun N-terminal kinase (JNK) and TNF 
contribute to MP production from hepatocytes. Finally, we used the biosynthetic annexin V-
homodimer, Diannexin (or ASP8597 as it is now referred to), which binds with high affinity 
to phosphatidylserine (PS) and prevents IRI (10), to show that this protein substantially 
reduces production of MPs in vivo following onset of post-ischemic reperfusion, and that 
residual Diannexin-coated MPs no longer exert pro-inflammatory or platelet-activating 
effects. 
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MATERIALS AND METHODS 
Murine model of partial hepatic IRI and administration of Diannexin  
Groups (n=10) of male C57BL6 mice age 8-12 weeks were anesthetized (ketamine 
100mg/kg, xylazine 20mg/kg) and subjected to partial hepatic ischemia as reported (8,10). 
Temgesic 0.05mg/kg is administered subcutaneously to animals on abdominal wound 
closure to provide post-operative analgesia during the recovery period. After 15min-24hr 
reperfusion, animals were again anesthetized were humanely killed by exsanguination. 
Blood and livers were collected (8,10). One group (sham) of control mice was subjected to 
anesthesia and sham laparotomy. Where indicated, Diannexin (1mg/kg) (or saline vehicle) 
was administered via lateral tail vein (iv), 5 min prior to hepatic IRI. Protocols for N-
acetylcysteine (NAC) pre-treatment in mice are described in detail in Supplementary 
Methods. 
 
Ethics statement 
The above animal protocols were approved by the Australian National University’s Animal 
Ethics Committee (protocol approval number #A2012/20) and conduct of experiments 
complied with the highest international criteria for humane care. 
 
Assessing severity of liver injury and cell viability  
Liver injury was determined by serum alanine aminotransferase (ALT). In primary 
hepatocytes, lactate dehydrogenase (LDH) release was measured with the CytoTox-96-non-
radioactive cytotoxicity assay (Promega, Madison, WI), and cell viability by 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) assay. 
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Isolation of murine primary hepatocytes and liver leukocytes 
           Primary hepatocytes (>95% purity, >90% viability by trypan blue exclusion) were 
isolated from murine livers using collagenase perfusion (37
o
C; 8mL/min), seeded (5 x 10
6
 
cells/100mm) in collagen 1-coated petri dishes and cultured in Williams-E (Gibco, St Louis, 
MO) supplemented with 10% heat-inactivated fetal bovine serum. To derive liver 
leukocytes, we used mechanical dissociation and centrifugation. Leukocytes were prepared 
in dextran (3%), then enriched for neutrophils by separation  by Ficoll-Paque
TM 
gradient, 
before semi-purified neutrophils were resuspended in RPMI. We simulated IRI in vitro 
using a hypoxia-reoxygenation (HR) chamber (Billrups-Rothenberg, CA) primed with 
100% nitrogen for 15min to establish total hypoxia. Reoxygenation was established by 
flushing with 21% O2/74% N2/5% CO2 (‘normoxia’). Control cells were cultured 
identically except for continued 21% O2/74% N2/5% CO2. Additions to primary 
hepatocytes in specific experiments (EGTA, SP600125) used to study processes such as MP 
formation and JNK activity are detailed in the figure legends. 
 
Preparation of MPs and flow cytometry analysis (FACS)  
Blood was collected by cardiac puncture from anesthetized mice, spun for 15min 
(1,500g) and plasma re-centrifuged 2min (13,000g). MPs were sedimented from plasma 
supernatant by prolonged centrifugation (see Supplementary Methods for detailed MP 
isolation protocol). MPs were recovered from culture medium of primary hepatocytes using 
a similar protocol. Thereafter, MP pellets were resuspended in phosphate-buffered saline 
(PBS) before FACS analysis. We measured MP size using nanofluorescent polystyrene 
particle beads and FACS (Spherotech, IL). The gating strategy employed was based on size 
of MPs, 0.1 - 1 m thereafter, analyses of MP subpopulations were carried out using cell-
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derived markers/tags (Supplementary Table 1). FACS ARIA II (Becton-Dickinson, San 
Jose, CA) was utilized to sort MPs and FlowJo 2009 V.7.5 (Tree Star, Ashland, OR) 
software for analyses and generation of dot plots. 
 
PS detection by ELISA 
MP production was determined semi-quantitatively by measuring phosphatidylserine 
(PS)-positive particles in the circulation (Zymuphen MP Activity, HYPHEN BioMed, 
France; see Supplementary Methods). It is acknowledged that this method may also detect 
PS on apoptotic bodies. For this reason, we also employed a gated FACS strategy to isolate 
a purer fraction of MPs (or exosomes), as discussed later. 
 
Cellular origin of MPs and their bioactive lipids 
To identify their cellular origin, MPs from mice subjected to IRI were freshly 
prepared in platelet-free plasma and incubated with the following cell-specific, FITC-
labeled monoclonal antibodies: Annexin V, VE-cadherin (CD144), CD41, CD62P, CD1d 
tetramer, CD8, F4/80, Ly6G or isotype-matched control antibodies (Supplementary Table 
1). We used FACS to determine the relative proportions of each subset of cell-derived MPs. 
To assay MP bioactive lipid composition, pellets obtained after 60min ischemia, 15min and 
2hr reperfusion, were analyzed for F2-isoprostanes (lipid oxidation marker) and fatty acids 
by combination gas chromatography mass spectrometry (GCMS)/liquid chromatography 
tandem mass spectrometry (LC/MS/MS) (S20,S21). 
 
 
                                                                                                                      
    
11
Western blot analysis of ICAM-1, VCAM, E-selectin, P-selectin, VE-cadherin, ASGPR, 
IκB-α, COX-2, PKC-JNK1/2, phosphorylated-JNK and measurement of serum TNF 
20μg of MP protein (Bradford assay) was resolved by 12% SDS-PAGE under 
reducing conditions, transferred to PVDF membranes and probed for the proteins detailed in 
Supplementary Methods. Serum TNF was measured by ELISA (R & D Systems, 
Minneapolis, MN). 
 
Transwell migration assay 
Neutrophil subpopulations of hepatic leukocytes were placed in 96 well chambers 
(ThinCert
TM
, Germany) fitted with porous PET membrane (8.0m pore diameter) inserts. 
The lower compartment was seeded with MPs, as specified in figure legends. In control 
wells (to correct for chemokinesis), equal concentrations of chemoattractants, IL-8 
(10ng/ml) or TNF (50ng/ml) were added above and below the membranes. After incubation 
for 24hr at 37°C, any non-migrated leukocytes were removed by washing with PBS twice 
and leukocytes that had migrated to the underside of the membrane, or which were present 
in the lower wells (stained with Giemsa-Wright) were counted. To ascertain effect of test 
compounds on transmigration potential, MPs were pre-treated with 1mM N-acetylcysteine 
(NAC) or Diannexin (4g/ml) for 1hr 37°C; thereafter, MPs were washed/resuspended in 
PBS then recovered by prolonged centrifugation twice (see Supplementary Methods for 
detailed MP protocol) prior to the transwell migration assay.  
 
Measurement of mitochondrial membrane potential (MPT) and oxidative stress  
We used tetramethylrhodamine methyl ester (TMRM)(Sigma, St Louis, MO) fluorescence 
as a marker of mitochondrial membrane potential (ΔΨm), 2,7-dichlororodihydrofluorescein 
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diacetate (DCFH2-DA, Sigma, St Louis, MO) fluorescence for oxidative stress 
(Supplementary Methods). The assay was performed using William’s E media in view of 
primary hepatocyte cultures studied; the solvent for DCFH2-DA was PBS at a final 
concentration of 10M. 
 
Statistical analyses 
Analysis of variance (ANOVA) with Tukey post-hoc analysis was used for the 
comparison of data from different experimental groups. Results presented as mean  SD, 
significant P < 0.05. 
 
 
RESULTS 
PS-containing MPs shed during post-ischemic reperfusion bear markers of endothelial 
cells, platelets, inflammatory cells and hepatocytes 
By an assay which quantifies surface PS, we demonstrated a significant increase in 
MP production during post-ischemic reperfusion from 15min, before serum ALT increased 
(Fig.1A,Table 1). We acknowledge that this assay would also determine PS-positive 
apoptotic fragments (see later comment).  MP production/detection persisted through the 
early and late phases of hepatic IRI (30min, 2hr) to reach peak plasma levels at 24hr 
reperfusion (Table 1). The time discrepancy between early increases MP and eventual rise 
in ALT levels (Fig.1Bi) indicates that the production of MPs precedes and does not simply 
reflect hepatic injury in IRI. We also measured serum hyaluronic acid (HA, Supplementary 
Methods) whose increase partially reflects the degree of SEC dysfunction or release from 
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the surface glycocalyx of SECs during post-ischemic reperfusion. Following 60min 
ischemia and 15min reperfusion, serum HA increased strikingly compared to sham-operated 
mice (Fig.1Bii) reflecting very early release from SECs during reperfusion. 
 
In order to establish the nature of MPs that circulate during hepatic IRI, we first used 
FACS gating to determine their size. We then partially characterized their cells of origin by 
incubation with fluorescent-labeled mAbs directed at molecules specific or relatively 
specific (in the case of CD62P) to different cell types (S22, Supplementary Table 1). MPs 
obtained post-IRI varied from 0.45 - 1m (Fig.1C). MPs appeared to be released in a time-
dependent manner during post-ischemic reperfusion (Fig.1A), and like serum ALT increase, 
reached peak levels at 24hrs reperfusion (Fig.1A,1Bi). MPs produced early (15, 30min) in 
reperfusion were enriched for endothelial cell (CD144, CD62P for activated SECs), platelet 
(CD41, CD62P also for activated platelets) and neutrophils (Ly6G) markers, indicating 
predominant origins from SECs, platelets and neutrophils. In addition, NK-T cell (CD1d 
tetramer) and CD8 T-cell markers were also expressed (Fig.1Ci). By 2hr reperfusion, 
markers of Kupffer cells/macrophages (F4/80) were more conspicuous on MPs (Fig.1Ci,ii), 
while NK-T cells and CD8 markers diminished (Fig.1Ci).  To confirm co-location of cell-
specific markers with 0.45 - 1m  MPs (excluding most apoptotic bodies – see earlier), we 
established that subsets of MPs released post-IR double stained positive for Annexin V, as 
well as CD144, CD41, CD62P, F4/80 and Ly6G (Fig.1Cii). 
 
As an additional approach to MP cell-source characterization, we performed 
immunoblot analysis of MP proteins. At 15min reperfusion, VE-cadherin, E-selectin 
(endothelial cell proteins) and vascular adhesion molecule (VCAM-1) were detected 
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(Fig.1D,E). By 30min, P-selectin (platelets) and ICAM-1 were also detectable. At 2hr, all 
the above proteins were substantially enhanced in MPs, with a dramatic increase in 
hepatocyte-specific asialoglycoprotein-receptor (ASGPR) as well as VE-cadherin 
(Fig.1D,E).  
 
MPs shed during post-ischemic reperfusion contain bioactive lipids 
As expected from their plasma membrane origin, MPs contain 
lysophosphatidylcholine (lysoPC), arachidonic acid (AA) metabolites and oxysterols (S23-
S25). Because of their potential relevance to inflammation and coagulation, we assayed the 
following bioactive lipid species within MPs obtained during the early phase (15min, 2hr) 
of post-ischemic reperfusion: (i) AA metabolites – prostaglandins, leukotrienes, 
hydroxyeicosatetraenoic acid , epoxyeicosatrienoic acids, F2-isoprostanes, (ii) specific 
phospholipids namely lysoPC, platelet activating factor (PAF), lysoPAF, PS, PE, and (iii) 
cholesterol oxidation products (oxysterols). At both reperfusion times, samples contained a 
range of fatty acids (palmitic, stearic, oleic, linoleic). Whereas MPs at 15min (ultra-early) 
reperfusion contained only a trace of AA, those at 2hr were enriched with AA (3.6µg total 
or 6g/mg protein). Samples also contained increased F2-isoprostanes derived from free 
radical oxidation of AA: at 15min, 0.40ng; 2hr, 0.44ng (Fig.1F) compared to those derived 
from sham-operated mice.  Thus, MPs released during the first 2hr of post-ischemic 
reperfusion contain several lipid molecules known to trigger inflammation and injury.  
 
MPs generated during hepatic IRI promote neutrophil migration and activate platelets 
 In order to test our hypothesis that MPs originating from SECs, inflammatory cells 
and platelets incite the early inflammatory/injury response in IRI (10,17), we tested whether 
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circulating MPs isolated in these experiments could to promote neutrophil recruitment. 
Addition of MPs generated by IRI (Fig.2Ai), as well as those from specific cell types 
(Fig.2Aii, particularly CD62P: activated platelets, F4/80: macrophages) to these chambers 
enhanced transmigration of leukocytes obtained from normal mouse liver in a dose-
dependent manner. In contrast, MPs pre-treated with N-acetylcysteine (NAC), a ROS and 
reactive nitrogen species scavenger, inhibited leukocyte transmigration in response to MPs 
(Fig.2Ai).  Because the overall neutrophil responses elicited by cell-specific subtypes of 
MPs were similar to those from the ‘mixed’ pool of MPs derived at 2hr reperfusion, we 
used the latter for subsequent studies. Such MPs activated platelets derived from sham-
operated mice as shown by enrichment of CD62P (activated platelets) in relation to CD41 
(all platelets)(S26) compared to PBS-treated controls (Fig.2B). Collectively, these findings 
are consistent with our hypothesis that MPs liberated during liver IR from SECs and other 
cell types induce neutrophil migration and activate platelets. 
 
MPs generated during hepatic IRI induce injury in primary hepatocytes by a process that 
involves oxidative stress and mitochondrial membrane permeability transition 
Because of their bioactive lipid content and potentially reactive oxygen 
intermediates and other pro-oxidants, MPs could also be directly cytopathic to hepatocytes. 
If so, this could, at least partially, contribute to the presence of hepatocyte-specific markers 
(ASGPR-positive) on MPs that circulate 2 and 24hr post-IR. To test this, we incubated 
primary murine hepatocytes (cultured in Williams E media) with MPs isolated from mice 
subjected to ischemia/2hr reperfusion. Within 30min, these MPs adhered to hepatocytes, 
while endocytosis clearly evident by 1hr (Fig.2C). This uptake process was inhibited by 
hypertonic sucrose (0.45M) which blocks endocytosis (Fig.2C)(S27). Following engulfment 
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of MPs (and not in control hepatocytes to which vehicle alone was added), hepatocyte 
injury was evident by LDH leakage (Fig.2D). Such MP-induced hepatocyte injury was 
particularly striking for F4/80 positive-MPs, which is consistent with the proposed role of 
KCs in hepatic IRI (Fig.2E).   
 
 To elucidate the mechanism by which IRI-related MPs injure hepatocytes, we used 
confocal microscopy of TMRM fluorescence (S28) to show how addition of MPs caused 
MPT, a phenomenon blocked by cyclosporine A (CyA)(Fig.3A). Further, we observed 
evidence of oxidative stress in MP-treated primary hepatocytes which could be abrogated by 
the antioxidant, N-acetylcysteine (NAC) in DCFH2-DA studies (Fig.3B). Thus, MPs induce 
oxidative stress in hepatocytes and provoke MPT whilst primary hepatocytes can be 
‘rescued’ from MP-related injury by co-treatment with an antioxidant or MPT inhibitor.  
 
 The effect of NAC on MPs release was further clarified by administering this potent 
antioxidant to mice (150mg/kg ip, Supplementary Methods) 5min prior to 60min ischemia 
and 24hr reperfusion. NAC significantly inhibited MP release and was profoundly 
hepatoprotective against IRI compared to naïve mice (Supplementary Fig.1A,B). Moreover, 
NAC greatly diminished the oxidative potential of MPs in primary hepatocytes and in vivo, 
as shown by a marked reduction in glutathione oxidation (oxidized glutathione/reduced 
glutathione, GSSG/GSH, Supplementary Fig.1C,D). 
 
MPs initiate post-ischemic inflammatory responses by activating NF-B in hepatocytes 
To further define their pro-inflammatory potential, MPs from mice subjected to IRI 
(as well as those derived from primary hepatocytes subjected to hypoxia-reoxygenation 
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[HR], described later), were probed for adhesion molecules. As mentioned earlier, MPs 
isolated at 15min reperfusion bear appreciable VCAM-1, E-selectin and P-selectin, while 
ICAM-1 is expressed on MPs shed at 30min reperfusion, and VE-cadherin is detected at 2 
and 24hr (Fig.1D,E). Thus, the profile of pro-inflammatory adhesion molecules borne on 
MPs differs with reperfusion time. Further, it recapitulates the suite of different adhesion 
molecules known to be expressed in livers subject to IRI (1-6). 
 
 Addition of MPs to primary hepatocytes likewise induced ICAM-1 and VCAM-1, and 
up-regulated pro-inflammatory COX-2 and PKC- protein expression (Fig.3C,D). MPs also 
activated c-jun N-terminal kinase (JNK)(Fig 3E), a known mediator of hepatocyte injury in 
IRI (1-6). To establish the effects of MPs on NF-B activation, we determined degradation 
of cytosolic IB-, and show that MPs caused a dose-dependent decrease in IB-α (Fig.3F). 
 
Hypoxia-reoxygenation leads to MP formation from primary hepatocytes by an oxidative 
stress and calcium-dependent process  
 In order to simulate the in vitro conditions for MP formation relevant to hepatic IRI in 
vivo, we exposed primary hepatocytes to 4hr hypoxia followed by 24hr reoxygenation. This 
liberated MPs, whereas hepatocytes subjected to normoxia alone did not (Fig.4A). CyA 
significantly diminished MP release after HR and markedly reduced cell injury (Fig.4B). To 
establish more directly that oxidative stress is responsible for MP generation, we incubated 
primary murine hepatocytes from mice with escalating doses of H2O2. At 20M or higher, 
H2O2 caused generation of MPs from primary hepatocytes (Fig.4C), a process abrogated by 
addition of 1mM EGTA, a potent Ca
2+
 chelator (S28), thereby abrogating activity of Ca
2+–
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dependent proteases such as calpain. These findings suggest that MP release from 
hepatocytes is triggered by oxidative stress and is Ca
2+
-dependent.  
 
TNF augments JNK-dependent MP formation by primary hepatocytes, as well as in mice 
after IRI 
TNF levels increase strikingly during liver IR, and an injection of high dose TNF 
prior to IR exacerbates liver injury (2,8) as well as SEC dysfunction by serum hyaluronic 
acid release (Fig.5A). TNF is a potent agonist of endothelial MP vesiculation and 
contributes to MP production in vitro (S29). It is therefore of interest to establish whether 
MPs stimulate TNF release in primary hepatocytes. As shown in Fig.5B, addition of 30 and 
60nM of MPs for 1hr under normoxic conditions provoked at least 4-fold stimulation of 
TNF production from hepatocytes. Conversely, incubating primary hepatocytes with 2nM 
TNF triggered perceptible MP production at 1hr, increasing significantly by 24hr, by a 
process abrogated by addition of SP600125 at concentrations for which it is a specific JNK 
inhibitor (Fig.5C). Finally, to establish whether TNF has similar effects on MP release in 
vivo, we injected murine TNF intravenously (5g/kg) 5min prior to onset of 60min 
ischemia, then measured MP production. The results show that TNF augments MP 
production in vivo during hepatic IR (Fig.5D), reaching a maximal response at 2hr 
reperfusion.  
 
The annexin V-homodimer, ASP8597 (Diannexin) inhibits MP production after hepatic 
IRI and reduces platelet activation  
Because Annexin V efficiently binds to MPs (most likely to everted PS 
residues)(S22), we investigated whether such a strategy would also block MP production 
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(Fig.6A) and prevent hepatic IRI. Diannexin is a biosynthesized human recombinant 
homodimer of annexin V that exerts considerable hepatoprotection against IRI in our 
murine model (Fig.6Bi); its efficacy associated with reduced swelling and detachment of 
SECs from their basement membrane, decreased hepatic expression of pro-inflammatory 
ICAM-1, VCAM and MIP-2, and abrogated leukocyte and platelet adherence to SECs 
(9,10). To establish whether this protective action involves attenuation of MP release, we 
injected mice with Diannexin (1mg/kg), 5min prior to hepatic ischemia and measured MP 
production during reperfusion. At all timepoints, Diannexin significantly diminished MP 
release, liver and SEC injury (by serum ALT and HA respectively) compared to naïve mice 
(Fig.6Bi,1Bii, Table1). By FACS, Diannexin not only substantially reduced MP production, 
it also altered the profile of cell markers detected on the residual trivial quantities of MPs 
derived (Fig.6A vs Fig.1C). Thus, these residual MPs displayed reduced markers for 
endothelial cells (CD144), platelets (CD41) and activated platelets (CD62P)(Fig.6A) 
confirming our proposal that the major effect of Diannexin is on SECs and platelets, and 
occurs early during post-ischemic reperfusion (10). Further, the protective efficacy and 
suppression of MP production conferred by Diannexin is sustained into late reperfusion 
(Fig.6Bi).  
 
Incubation of platelets derived from sham-operated mice with MPs isolated from 
mice after 60min ischemia/2hr reperfusion resulted in a significant induction of activated 
(CD62P+ve) platelets (Fig.6Bii). However, if such MPs were “Diannexin-treated” (4g/ml) 
then exposed to ‘normal’ platelets in vitro, this strategy yielded significantly reduced 
populations of CD62P+ve platelets compared to those exposed to “Diannexin-naïve” MPs 
(Fig.6Bii) 
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Diannexin blocks the pro-inflammatory and pro-oxidant properties of MPs released 
during hepatic IRI 
 While Diannexin reduced total MP production after IRI, the attendant abrogation of 
liver injury by ALT (Fig.1Bi) and histology was even more complete (10). This would be 
explained if MP production was only part of the hepatoprotective effect of Diannexin, or if 
residual MPs failed to exert their pro-inflammatory and platelet-activating properties. To 
test the latter proposal, MPs from Diannexin-treated animals subjected to IRI were analyzed 
for the expression of hepatocyte-specific marker ASGPR, and inflammatory adhesion 
molecules, VCAM-1, ICAM-1 and E-selectin by immunoblotting. MPs from Diannexin-
treated mice yielded significantly reduced markers for cells of hepatocyte origin (Fig.6C,D). 
While VCAM-1, ICAM-1 and E-selectin were strikingly upregulated in MPs released in 
naïve mice during late reperfusion (24hr)(Fig.1D,E), their expression was significantly 
mitigated after Diannexin treatment (Fig.6C,D). In in vitro experiments, incubation of MPs 
isolated from mice after 60min ischemia/2hr reperfusion with Diannexin in vitro, markedly 
inhibited leukocyte transmigration potential in chemotaxis studies (Fig.6E).  
  
 The oxidation status of MPs derived from Diannexin-treated mice was determined by 
oxidized glutathione/reduced glutathione (GSSG/GSH) measurements. As depicted in 
Supplementary Fig.1C, glutathione oxidation was significantly diminished by Diannexin-
pretreatment compared to levels in MPs derived from naïve mice. Taken together, this suite 
of interventions confirm that Diannexin effectively abrogates cell-specific injury 
particularly to SECs, hepatocytes, reduces platelet-activation, the pro-inflammatory and pro-
oxidant properties of MPs liberated during liver IR and that these findings strongly correlate 
with hepatoprotection by serum ALT (Fig.6Bi) . 
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 DISCUSSION  
  MPs are cell membrane fragments shed upon injury or apoptosis whose circulating 
levels have been reported as biomarkers for such vasculopathies as acute myocardial 
infarction, ischemic stroke, peripheral vascular disease and eclampsia (11-13). In the present 
study, we first established that MPs are liberated during hepatic IRI, arising in the earliest 
stages from activated or injured SECs, and in the later phases, involving platelets, various 
inflammatory cells and eventually hepatocytes. We then demonstrated that MPs actively 
contribute to the pathogenesis of IRI via their well-known pro-inflammatory effects and 
their role as platelet-activating agents. We also provided evidence for an entirely novel 
pathway of direct hepatocyte injury in IRI. Finally, our novel findings clarify the 
mechanism for the powerful therapeutic efficacy of the annexin V dimer, Diannexin, which 
would be expected to “seek and hide” exposed PS residues on circulating MPs (10). 
  
  MPs are released within minutes of IR or hypoxia-reoxygenation. This is followed 
by further cascades of shedding from a variety of cell types over several hours. Although the 
present data are confined to small MPs (0.45 – 1 m) that comprise exosomes rather than 
apoptotic bodies, it is possible that larger MPs (aptosomes) also play a role in IRI, as might 
lipid rafts and smaller MPs. This requires further study using newer technology for MP 
purification. However one of the major new findings of the present studies is that circulating 
MPs are engulfed by hepatocytes, and this causes ROS generation with induction of MPT as 
a pathway to cell injury and necrotic cell death. In keeping with reports in other cell types 
(12,13), our results also provide direct evidence that hepatocyte-derived MPs cause dose-
dependent TNF release from other hepatocytes, a process that is ROS-dependent and can be 
abrogated by NAC in vivo and in vitro. This is potentially important in propagation of liver 
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IRI as TNF further amplifies MP shedding in vivo during hepatic IRI, also by a redox and 
calcium-dependent process.  Interruption of TNF release with NAC, an agent already in use 
in clinical practice for acetaminophen overdose, so as to mitigate propagation of liver IRI is 
worthy of further study in humans after hepatic surgery or liver transplantation.  
 
  The phospholipid composition of each leaflet of the plasma membrane bilayer differs; 
PS and PE aggregate in the inner leaflet, PC and sphingomyelin are present in the outer 
layer (17). Loss cellular energy, or after cytoskeletal disruption (as in apoptosis) leads to 
loss of membrane integrity with eversion of the negatively charged PS and PE. Hence, MPs 
liberated after cellular injury usually bear PS on their extruded surfaces. Other lipid 
molecules with biological activity are contained within MPs including lysoPC, AA 
metabolites (including F2-isoprostanes) and oxysterols. Both the nature of cellular insult 
and the cell type of origin influence MP constituents (11,S22). In our studies, MPs 
generated after 15min reperfusion contained only a trace of AA, but the amount escalated 
by 2hr reperfusion, and at this time highly pro-inflammatory F2-isoprostanes could also be 
detected. The nature of our studies in the whole mouse does not allow clarification of why 
MP lipid composition changes post-ischemic time, other than to note that AA and F2-
isoprostanes which were detected at 2hr but only in vanishingly small quantities at 15min, 
were more likely to arise from platelets and macrophages rather than SECs, other 
inflammatory cells and hepatocytes. 
 
   In order to understand how MPs could exert pro-inflammatory effects, as 
demonstrated by the neutrophil migration studies, we probed MP pellets for adhesion 
molecules. As early as 15min reperfusion, circulating MPs express VCAM-1, E-selectin and 
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P-selectin (Fig.1D), while ICAM-1 and VE-cadherin were detected later. Further, our in 
vitro approaches demonstrated unambiguously that the MPs which circulate during post-
ischemic reperfusion with the most potent pro-inflammatory properties are KC/macrophage- 
and platelet-derived. The present results clearly indicate that MPs engulfment by 
hepatocytes leads to degradation of IκB-α, the cytosolic inhibitor of NF-B. Activation of 
NF-B in livers subjected to IR upregulates numerous pro-inflammatory genes such as 
COX-2 and PKC- that participate in liver inflammatory recruitment and cell death 
(2,3,5,6). These effects were observed in the context of MP stimulation, together with 
elaboration of TNF and activation of JNK, both of which are known pro-inflammatory 
pathways in hepatic IRI injury (8,S30). Thus, in addition to direct effects of redox stress, 
TNF and JNK activation, MP engulfment is another node in the pathways to pro-
inflammatory signaling during IRI. Importantly, as already mentioned, this is another site at 
which NAC could exert therapeutic effects. 
  
  The formation of membrane-derived MPs is dependent on increased intracellular ionic 
calcium which activates calpain. We and others have shown that hepatic calpain activity 
escalates with increasing post-ischemic reperfusion time (Supplementary Fig.2) and calpain 
inhibition by calpeptin significantly reduced MP production in the present experiments 
(S31). Whether agents to sequester mobilisation of ionic calcium or calpain antagonists 
could have therapeutic application in hepatic IRI requires further study. Our previously 
ultrastructural studies revealed extensive blebbing of the sinusoidal endothelium at 30min 
post-ischemic reperfusion (10). The present results show this is the origin of the MPs that 
circulate within 15 min of hepatic IRI. This potentially does have therapeutic implications 
for early intervention in IRI. Thus, we addressed the suggestion of Albano (17) that 
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Diannexin, by binding to PS, might inhibit MP release, thereby interfering with the 
inflammatory and procoagulant effects normally executed by MPs. This was shown 
unambiguously to be the case. Moreover, residual MPs from Diannexin pre-treated mice 
displayed less pro-inflammatory and pro-oxidant potential and activity. Lipid rafts of the 
cell membrane may also play a role in MP release (S32); annexin V is known to bind to 
lipid rafts of cells and to PS with high affinity (S33). It is therefore also plausible that 
Diannexin, by binding to lipid rafts, prevents the distortion of the plasma membrane surface 
that is a pre-requisite for vesicle-budding to form MPs.  
 
  In summary, our data indicate that MPs are released during liver IRI and that these 
MPs are pro-inflammatory, platelet activating, and directly pathogenic to hepatocytes in 
vitro. By simulation experiments, we have shown that MP production, at least in 
hepatocytes, is modulated by oxidative stress, TNF and calcium fluxes, known pathogenic 
factors in IR. Not all MPs are the same; by selective study of cell-derived MP subfractions, 
we showed those from KCs/macrophages and platelets may be particularly pro-
inflammatory and particularly injurious to hepatocytes. Whether this is due to higher AA 
and F2-isoprostane content requires further investigation. Meanwhile, the clear finding that 
Diannexin protects against MP production and MP-induced injury has therapeutic 
implications. Thus, we have already shown that Diannexin exerts both preventive and 
therapeutic effects against hepatic IRI, the latter up to 24 hrs after post-ischemic liver 
reperfusion (10). Taken together, the present results reveal pivotal pathogenic mechanisms 
that initiate and likely perpetuate hepatic IRI during liver surgery and transplantation. 
Implication of MP formation should facilitate the development of clinically applicable and 
effective strategies against IRI.  
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FIGURE LEGENDS 
Figure 1 
MP production is increased in hepatic IRI 
A. MP release (concentration expressed as phosphatidylserine, PS equivalent in nM) and 
Bi,ii serum ALT and hyaluronic acid (HA) after 60min ischemia and indicated reperfusion 
times in naïve and Diannexin-treated mice (n=10 per cohort). 
* p<0.05 all experimental groups vs. sham 
‡ p<0.05 IRI 2hr vs. 30min reperfusion 
# p<0.05 IRI 24hr vs. 15min, 30min and 2hr reperfusion 
§ p<0.05 Diannexin vs. no Diannexin at 24 hr reperfusion 
C. FACS plots demonstrating MPs released early in reperfusion are composed 
predominantly of endothelial-derived/CD144 remnants while in late reperfusion, MPs are 
largely from leukocytes and hepatocytes. (Ci) FACS data depicted as % bearing cell-
specific markers (Supplementary Table 1). Note, because individual MPs are cell fragments 
and may potentially fuse, MPs can bear more than 1 cell-marker and therefore, the sum of 
all expressed markers may feasibly exceed 100% (Supplementary Methods). (Cii) Annexin 
V was utilized to analyze for double positive events together with cell-specific markers 
CD144, CD41, CD62P F4/80 and Ly6G. * p<0.05 IRI groups vs. sham 
D. MPs bear ASPGR (hepatocytes) and VE-cadherin (SECs), VCAM-1, ICAM-1, E-
selectin, P-selectin. MPs obtained from mice subjected to liver post-IR at indicated times.  
Blots representative of three similar experiments.  
E. Image analyses/quantification show upregulation of adhesion molecules especially at 2, 
24hr reperfusion.  
* p<0.05 IRI vs. sham 
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& p<0.05 IRI 2 and 24hr vs. IRI 15 and 30min reperfusion 
%p<0.05 IRI 30min vs. IRI 15min reperfusion 
# p<0.05 IRI 24hr vs. 15,30min, 2hr reperfusion 
§ p<0.05 IRI 2hr vs. 15min reperfusion   
‡  p<0.05 IRI 2hr vs. IRI 30 min reperfusion 
F. MPs at 15min and 2hr reperfusion contain increased levels of F2-isoprostanes compared 
to those derived from sham-operated mice by GCMS and LC/MS/MS (normalised to total 
AA detected).  
 
Figure 2 
MPs are directly pathogenic to primary hepatocytes, incite neutrophil recruitment and 
activate platelets 
Ai. Hepatic neutrophils were derived by liver perfusion and chemotaxis measured in 
ThinCert
TM
 chambers. Lower compartments were seeded with MPs from mice subjected to 
2hr post-ischemia-reperfusion (IR), IL-8 or TNF- as chemoattractants (IL-8,TNF:positive 
controls) and incubated (1hr, 37°C). Co-treatment of MPs with 1mM NAC reduced 
neutrophil transmigration. To ascertain effect of N-acetylcysteine (NAC) on transmigration 
potential, MPs were pre-treated with 1mM NAC for 1hr 37°C; thereafter, MPs were 
resuspended in PBS then recovered by prolonged centrifugation (see Supplementary 
Methods for detailed MP isolation protocol) prior to the transwell migration assay.  
Aii.  Addition of MPs generated by IRI from specific cell types (significantly, activated 
platelets and endothelial cells [CD62P], and macrophages [F4/80]; not resting SECs 
[CD144]) to these chambers enhanced transmigration of leukocytes. * p<0.05 experimental 
groups vs. control 
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B. Platelets from sham-operated mice treated with 60nM MPs (from mice subjected to 2hr 
post-IR) for 30min, labelled with CD62P (activated platelet and endothelial cell marker) and 
subjected to FACS. * p<0.05 experimental groups vs. control 
C. MPs from mice subjected to 2hr post-IR co-incubated with primary hepatocytes. By 
30min, MPs adhered to hepatocytes and were endocytosed at 1hr (first row/top panel of 
figures: 0min, 30min, 60min); engulfment was inhibited by 0.45M sucrose (second 
row/lower panel of figures: 30min, 60min). 
D. Primary hepatocytes treated with increasing concentrations of MPs derived from mice 
subjected to 2hr post-IR. LDH leakage and cell viability (MTT assay) in MP-treated cells 
compared with PBS-controls. (E) Primary hepatocytes treated with increasing 
concentrations of MPs derived from specific cell types (CD62P: activated platelets and 
endothelial cells, CD144: SECs, F4/80: macrophages) obtained from mice subjected to 2hr 
post-IR. 
Experiments performed in triplicate in MP-preparations from 4 mice (n=12). *p<0.05 
experimental groups vs. control 
 
Figure 3 
MPs invoke mitochondrial permeability transition, oxidative stress, adhesion molecule 
expression and activate NF-B in hepatocytes 
A. Hepatocytes loaded with 50nM TMRM (red fluorescence), 1M DCFH2-DA (green 
fluorescence) and placed in chambers at 37°C for 15min. MPT occurred with increasing MP 
concentrations, blocked by 1M CyA.  
B. 1mM of NAC inhibited oxidative stress generated by MPs. 
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C, D. Primary hepatocytes were exposed to 60nM of MPs derived from liver 2hr post-IR 
and pro-inflammatory molecules COX-2 and PKC-determined (WB) as well as (E) JNK-
1/2 (46kDA, 54kDA) activation (phospho-JNK). 
* p<0.05 experimental groups vs. control 
+ p<0.05 30 and 60nM vs. 12nM MPs 
† p<0.05 MPs 60nM vs. 30nM MPs 
F. MPs activate NF-B in primary hepatocytes, by IκB-α degradation (immunoblots). Blots 
represent three experiments conducted in triplicate (n=9). 
* p<0.05 experimental vs. control 
 
Figure 4 
Hypoxia-reoxygenation and oxidative stress trigger MP release 
A. Primary hepatocytes were exposed to 4hr hypoxia followed by 24hr reoxygenation 
(Methods). Pretreatment with 1M CyA (MPT-inhibitor) for 2hr prior to HR attenuated MP 
release and (B) LDH leakage from hepatocytes subjected to HR. Controls: cells incubated in 
normoxic conditions. Experiments performed in triplicate.  
* p<0.05 experimental vs. control 
& p<0.05 hypoxia-reoxygenation  vs. CyA  
C. H202 causes MP primary hepatocytes to form MPs, which is attenuated by calcium 
chelation (EGTA) . Primary murine hepatocytes were incubated with H202 for 24hr. At 
10M or higher, H202 causes generation of MPs, while MP release is abolished by co-
administration of EGTA. Assays performed in triplicate.  
* p<0.05 experimental vs. control 
+p<0.05 EGTA vs. H202  
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Figure 5 
MPs stimulate TNF release and are themselves potent agonists of MP vesiculation in 
vivo 
A. Serum hyaluronic acid (HA) release increases in mice subjected to 60min ischemia and 
15min reperfusion; this is exacerbated by administration of TNF in vivo (mice injected with 
TNF 5g/kg iv vs. saline controls), 5min prior to 60min ischemia. 
* p<0.05 experimental vs. control 
B. TNF is produced by primary hepatocytes following addition of MPs derived from mice 
subjected to 2hr post-ischemic reperfusion. 
* p<0.05 experimental vs. control  
† p<0.05 60nM vs. 30nM MPs 
C. Primary hepatocytes were incubated with 2nM TNF for 1hr and 24hr in normoxic 
conditions.  SP600125 (20M in 0.1% DMSO) significantly attenuated TNF-stimulated MP 
release .  
* p<0.05 experimental vs. control 
‡ p<0.05 TNF vs. TNF+SP600125 
D. WT CL57BL6 mice were injected i.v. with TNF 5g/kg (saline for controls), 5min prior 
to 60min ischemia. MP production was measured in plasma at 15min, 30min, 2hr 
reperfusion. Liver IRI triggered MP production; TNF injection further augmented MP 
release reaching a maximum at 2hr. 
* p<0.05 experimental vs. control 
± p<0.05 IRI groups vs. sham TNF  
# p<0.05 30 min+TNF vs. IRI 30 min reperfusion 
§ p<0.05 2 hr+TNF vs. 2 hr reperfusion 
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Figure 6 
Diannexin attenuates release of MPs after hepatic IRI and decreases their pro-
inflammatory and deleterious potential  
MPs were obtained from mice pre-treated with 1mg/kg iv Diannexin 5min prior to 60min 
liver IR and results compared with vehicle-treated/naïve mice subject to IR. 
A. FACS revealed significantly reduced resting endothelial cell (CD144), resting platelet 
(CD41) and activated platelet and endothelial cell (CD62P) subsets compared to naïve (see 
Fig.1C).  
Bi. Serum ALT after 60min ischemia and indicated reperfusion times in naïve and 
Diannexin-treated mice (n=10 per cohort). 
* p<0.05 all experimental groups vs. sham 
§ p<0.05 Diannexin vs. 24 hr reperfusion 
Bii. Platelets were isolated from sham-operated mice and exposed to 60nM MPs (derived 
from mice subjected to 60min ischemia, 2hr reperfusion) in the absence or presence of 
4g/ml Diannexin. FACS then performed using CD62P to quantify activated platelet subset 
as a proportion of total platelets. 
* p<0.05 experimental vs. control 
# p<0.05 Diannexin vs. 60nM MPs 
 C, D. Hepatocyte-specific ASPGR, E-selectin and pro-inflammatory VCAM, ICAM-1 
protein expression diminished by Diannexin compared to naïve mice subjected to 60min 
ischemia and indicated reperfusion times.  
+ p<0.05 Diannexin vs. sham  
& p<0.05 Diannexin vs. naïve 
                                                                                                                      
    
31
E. Pre-treatment of MPs with Diannexin 4g/ml inhibited neutrophil transmigration in 
ThinCert
TM
 chambers. To ascertain effect of test compounds on transmigration potential, 
MPs were pre-treated with Diannexin (4g/ml) for 1hr 37°C; thereafter, MPs were 
resuspended in PBS then recovered by prolonged centrifugation twice (see Supplementary 
Methods for detailed MP isolation protocol) prior to the transwell migration assay.  
 
* p<0.05 experimental vs. control 
# p<0.05 Diannexin vs. 60nM MPs 
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TABLE 
Table 1  
Microparticles released at indicated reperfusion time after 60min hepatic ischemia in 
naïve and Diannexin-treated mice (n=10 per experimental group) 
 
 
 
 
*p<0.05 all experimental groups vs. sham 
@p<0.05 Diannexin vs. 15min reperfusion 
& p<0.05 Diannexin vs. 30min reperfusion 
# p<0.05 Diannexin vs. 2hr reperfusion 
§
 
p<0.05 Diannexin vs. 24hr reperfusion 
 
 
 
 
 
 
 
 
Experimental group, 
and reperfusion time 
Microparticles released (PS equivalent, nM) 
Naϊve Diannexin 
Sham 14.7 ± 5.52 12.5 ± 1.57 
15 min  48.1 ± 12.6  * 29.9 ± 3.25 * 
@
 
30 min  34.7 ± 12.8 * 20.1 ± 5.77 
&
 
2 hr  51.9 ± 10.9 * 35.2 ± 3.42 * 
#
 
24 hr 104 ± 25.6 * 44.8 ± 9.43 * 
§
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TMRM tetramethylrhodamine methyl ester 
VCAM-1 vascular cell adhesion molecule 1 
VE-cadherin vascular endothelial-cadherin  
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ABSTRACT  
 
BACKGROUND & AIMS: Ischemia–reperfusion injury (IRI) can cause hepatic failure 
after liver surgery or transplantation. IRI causes oxidative stress, which injures sinusoidal 
endothelial cells (SECs), leading to recruitment and activation of Kupffer cells and platelets 
(by unknown processes) and microcirculatory impairment. We investigated whether injured 
SECs and other cell types release microparticles (small fragments shed from outer leaf of 
the plasma membrane) during post-ischemic reperfusion, and whether such microparticles 
have pro-inflammatory, platelet-activating and pro-injurious effects that could contribute to 
IRI pathogenesis.  
METHODS: C57BL6 mice underwent 60 min of partial hepatic ischemia followed by 15 
min–24 hrs of reperfusion. We collected blood and liver samples, isolated and measured 
circulating microparticles, and determined protein and lipid content. To establish 
mechanism for production of microparticles, we subjected murine primary hepatocytes to 
hypoxia-reoxygenation. Finally, because microparticles express everted phosphatidylserine 
residues that are the target of annexin V, we analyzed the effects of an annexin V-
homodimer (Diannexin or ASP8597) on post-ischemia microparticle production and 
function. 
RESULTS: Microparticles were detected in the circulation 15–30 min after post-ischemic 
reperfusion, and contained markers of SECs, platelets, natural killer T cells, and CD8
+ 
cells; 
4 hrs later, they contained markers of macrophages. Microparticles also contained F2-
isoprostanes, indicating oxidative damage to membrane lipids. Injection of mice with tumor 
necrosis factor-increased microparticle formation, whereas Diannexin substantially 
reduced microparticle release and prevented IRI. Hypoxia-re-oxygenation generated 
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microparticles from primary hepatocytes by processes that involved oxidative stress and 
ionic calcium. Exposing cultured hepatocytes to preparations of microparticles isolated from 
the circulation during IRI caused injury involving mitochondrial membrane permeability 
transition. Microparticles also activated platelets and induced neutrophil migration in vitro. 
The inflammatory properties of microparticles involved activation of NF-B and JNK, and 
increased expression of E-selectin, P-selectin, ICAM-1, and VCAM-1. All these processes 
were blocked by coating microparticles with Diannexin.   
CONCLUSIONS: Following post-ischemic reperfusion of mouse liver, microparticles 
(mainly derived from SECs, platelets, and lymphocytes) circulate and can be taken up by 
hepatocytes, where they activate signaling pathways that mediate inflammation and 
hepatocyte injury. Microparticles also activate neutrophil recruitment and platelet activation 
directly. Diannexin prevents microparticle formation and subsequent inflammation. 
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INTRODUCTION 
Hepatic ischemia-reperfusion injury (IRI) remains an important complication of 
liver surgery and transplantation (1,2). In the early phase (first 2hr), hepatic damage is 
caused by oxidative stress, generated by Kupffer cells (KCs) with damage to sinusoidal 
endothelial cells (SECs) (1-6). The late phase (6-24hr) is mediated by hepatic recruitment of 
leukocytes and macrophages. These adhere to SECs that express adhesion molecules (E-
selectin, P-selectin, ICAM-1, VCAM-1) and secrete chemokines (5-8) in response to 
hypoxia, oxidative stress, and tumor necrosis factor- (TNF) (8). Platelets are essential for 
hepatic IRI (9); platelet clumps adhere to damaged SECs during the first 20 min of post-
ischemic reperfusion (10). The factors linking early SEC injury to inflammatory cell 
recruitment and platelet activation, with resultant microcirculatory impairment and 
hepatocyte injury have not been fully clarified. 
 
Microparticles (MPs) are small (0.1–1.0m) fragments shed from blebbing of the 
outer leaf of plasma membranes of activated cells, such as platelets, macrophages, 
endothelial cells, lymphocytes, and hepatocytes, or from cells undergoing apoptosis (11,12). 
They are important in promoting inflammation and thrombotic responses following vascular 
dysfunction (11-16). MPs harbour cell membrane proteins (used to identify their cellular 
origin) which also contain biologically active lipids. On their surface, MPs exhibit 
negatively charged phospholipids, chiefly phosphatidylserine (PS) which accounts for their 
pro-coagulant and pro-inflammatory properties (11-16). Levels of circulating MPs increase 
in acute coronary ischemia, myocardial infarction and pre-eclampsia, likely contributing to 
the associated leukocyte and platelet adhesion and obstruction of microvascular blood flow 
(11-13).  
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Involvement of MPs in the pathogenesis of liver disease has been suggested in 
cirrhosis and hepatitis (17-19) but has not been reported so far in hepatic IRI. We have 
described extensive blebbing of SEC plasma membranes during the first 20min of post-
IR(10), leading us to conceive the hypothesis that MPs originating from perturbed plasma 
membranes of SECs contribute to the microvascular inflammatory and platelet activating 
responses in hepatic IRI. In the present work, we conducted experiments in a well-validated 
murine model of partial hepatic IRI (8,10) to demonstrate time-dependent production of 
MPs in liver IRI, and to characterize their cellular derivation and lipid composition. We then 
determined the pathogenic effects of MPs, specifically their ability: (i) to cause hepatocyte 
injury directly, (ii) to activate platelets, (iii) to promote neutrophil recruitment, and (iv) to 
generate pro-inflammatory mediators, reactive oxygen species (ROS) and mitochondrial 
permeability transition (MPT)(7). 
To pursue these aims we used a variety of complementary in vitro and in vivo 
approaches. We subjected primary hepatocytes to hypoxia-reoxygenation (HR) and showed 
that mitochondrial injury, activation of the c-jun N-terminal kinase (JNK) and TNF 
contribute to MP production from hepatocytes. Finally, we used the biosynthetic annexin V-
homodimer, Diannexin (or ASP8597 as it is now referred to), which binds with high affinity 
to phosphatidylserine (PS) and prevents IRI (10), to show that this protein substantially 
reduces production of MPs in vivo following onset of post-ischemic reperfusion, and that 
residual Diannexin-coated MPs no longer exert pro-inflammatory or platelet-activating 
effects. 
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MATERIALS AND METHODS 
Murine model of partial hepatic IRI and administration of Diannexin  
Groups (n=10) of male C57BL6 mice age 8-12 weeks were anesthetized (ketamine 
100mg/kg, xylazine 20mg/kg) and subjected to partial hepatic ischemia as reported (8,10). 
Temgesic 0.05mg/kg is administered subcutaneously to animals on abdominal wound 
closure to provide post-operative analgesia during the recovery period. After 15min-24hr 
reperfusion, animals were again anesthetized were humanely killed by exsanguination. 
Blood and livers were collected (8,10). One group (sham) of control mice was subjected to 
anesthesia and sham laparotomy. Where indicated, Diannexin (1mg/kg) (or saline vehicle) 
was administered via lateral tail vein (iv), 5 min prior to hepatic IRI. Protocols for N-
acetylcysteine (NAC) pre-treatment in mice are described in detail in Supplementary 
Methods. 
 
Ethics statement 
The above animal protocols were approved by the Australian National University’s Animal 
Ethics Committee (protocol approval number #A2012/20) and conduct of experiments 
complied with the highest international criteria for humane care. 
 
Assessing severity of liver injury and cell viability  
Liver injury was determined by serum alanine aminotransferase (ALT). In primary 
hepatocytes, lactate dehydrogenase (LDH) release was measured with the CytoTox-96-non-
radioactive cytotoxicity assay (Promega, Madison, WI), and cell viability by 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) assay. 
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Isolation of murine primary hepatocytes and liver leukocytes 
           Primary hepatocytes (>95% purity, >90% viability by trypan blue exclusion) were 
isolated from murine livers using collagenase perfusion (37
o
C; 8mL/min), seeded (5 x 10
6
 
cells/100mm) in collagen 1-coated petri dishes and cultured in Williams-E (Gibco, St Louis, 
MO) supplemented with 10% heat-inactivated fetal bovine serum. To derive liver 
leukocytes, we used mechanical dissociation and centrifugation. Leukocytes were prepared 
in dextran (3%), then enriched for neutrophils by separation  by Ficoll-Paque
TM 
gradient, 
before semi-purified neutrophils were resuspended in RPMI. We simulated IRI in vitro 
using a hypoxia-reoxygenation (HR) chamber (Billrups-Rothenberg, CA) primed with 
100% nitrogen for 15min to establish total hypoxia. Reoxygenation was established by 
flushing with 21% O2/74% N2/5% CO2 (‘normoxia’). Control cells were cultured 
identically except for continued 21% O2/74% N2/5% CO2. Additions to primary 
hepatocytes in specific experiments (EGTA, SP600125) used to study processes such as MP 
formation and JNK activity are detailed in the figure legends. 
 
Preparation of MPs and flow cytometry analysis (FACS)  
Blood was collected by cardiac puncture from anesthetized mice, spun for 15min 
(1,500g) and plasma re-centrifuged 2min (13,000g). MPs were sedimented from plasma 
supernatant by prolonged centrifugation (see Supplementary Methods for detailed MP 
isolation protocol). MPs were recovered from culture medium of primary hepatocytes using 
a similar protocol. Thereafter, MP pellets were resuspended in phosphate-buffered saline 
(PBS) before FACS analysis. We measured MP size using nanofluorescent polystyrene 
particle beads and FACS (Spherotech, IL). The gating strategy employed was based on size 
of MPs, 0.1 - 1 m thereafter, analyses of MP subpopulations were carried out using cell-
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derived markers/tags (Supplementary Table 1). FACS ARIA II (Becton-Dickinson, San 
Jose, CA) was utilized to sort MPs and FlowJo 2009 V.7.5 (Tree Star, Ashland, OR) 
software for analyses and generation of dot plots. 
 
PS detection by ELISA 
MP production was determined semi-quantitatively by measuring phosphatidylserine 
(PS)-positive particles in the circulation (Zymuphen MP Activity, HYPHEN BioMed, 
France; see Supplementary Methods). It is acknowledged that this method may also detect 
PS on apoptotic bodies. For this reason, we also employed a gated FACS strategy to isolate 
a purer fraction of MPs (or exosomes), as discussed later. 
 
Cellular origin of MPs and their bioactive lipids 
To identify their cellular origin, MPs from mice subjected to IRI were freshly 
prepared in platelet-free plasma and incubated with the following cell-specific, FITC-
labeled monoclonal antibodies: Annexin V, VE-cadherin (CD144), CD41, CD62P, CD1d 
tetramer, CD8, F4/80, Ly6G or isotype-matched control antibodies (Supplementary Table 
1). We used FACS to determine the relative proportions of each subset of cell-derived MPs. 
To assay MP bioactive lipid composition, pellets obtained after 60min ischemia, 15min and 
2hr reperfusion, were analyzed for F2-isoprostanes (lipid oxidation marker) and fatty acids 
by combination gas chromatography mass spectrometry (GCMS)/liquid chromatography 
tandem mass spectrometry (LC/MS/MS) (S20,S21). 
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Western blot analysis of ICAM-1, VCAM, E-selectin, P-selectin, VE-cadherin, ASGPR, 
IκB-α, COX-2, PKC-JNK1/2, phosphorylated-JNK and measurement of serum TNF 
20μg of MP protein (Bradford assay) was resolved by 12% SDS-PAGE under 
reducing conditions, transferred to PVDF membranes and probed for the proteins detailed in 
Supplementary Methods. Serum TNF was measured by ELISA (R & D Systems, 
Minneapolis, MN). 
 
Transwell migration assay 
Neutrophil subpopulations of hepatic leukocytes were placed in 96 well chambers 
(ThinCert
TM
, Germany) fitted with porous PET membrane (8.0m pore diameter) inserts. 
The lower compartment was seeded with MPs, as specified in figure legends. In control 
wells (to correct for chemokinesis), equal concentrations of chemoattractants, IL-8 
(10ng/ml) or TNF (50ng/ml) were added above and below the membranes. After incubation 
for 24hr at 37°C, any non-migrated leukocytes were removed by washing with PBS twice 
and leukocytes that had migrated to the underside of the membrane, or which were present 
in the lower wells (stained with Giemsa-Wright) were counted. To ascertain effect of test 
compounds on transmigration potential, MPs were pre-treated with 1mM N-acetylcysteine 
(NAC) or Diannexin (4g/ml) for 1hr 37°C; thereafter, MPs were washed/resuspended in 
PBS then recovered by prolonged centrifugation twice (see Supplementary Methods for 
detailed MP protocol) prior to the transwell migration assay.  
 
Measurement of mitochondrial membrane potential (MPT) and oxidative stress  
We used tetramethylrhodamine methyl ester (TMRM)(Sigma, St Louis, MO) fluorescence 
as a marker of mitochondrial membrane potential (ΔΨm), 2,7-dichlororodihydrofluorescein 
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diacetate (DCFH2-DA, Sigma, St Louis, MO) fluorescence for oxidative stress 
(Supplementary Methods). The assay was performed using William’s E media in view of 
primary hepatocyte cultures studied; the solvent for DCFH2-DA was PBS at a final 
concentration of 10M. 
 
Statistical analyses 
Analysis of variance (ANOVA) with Tukey post-hoc analysis was used for the 
comparison of data from different experimental groups. Results presented as mean  SD, 
significant P < 0.05. 
 
 
RESULTS 
PS-containing MPs shed during post-ischemic reperfusion bear markers of endothelial 
cells, platelets, inflammatory cells and hepatocytes 
By an assay which quantifies surface PS, we demonstrated a significant increase in 
MP production during post-ischemic reperfusion from 15min, before serum ALT increased 
(Fig.1A,Table 1). We acknowledge that this assay would also determine PS-positive 
apoptotic fragments (see later comment).  MP production/detection persisted through the 
early and late phases of hepatic IRI (30min, 2hr) to reach peak plasma levels at 24hr 
reperfusion (Table 1). The time discrepancy between early increases MP and eventual rise 
in ALT levels (Fig.1Bi) indicates that the production of MPs precedes and does not simply 
reflect hepatic injury in IRI. We also measured serum hyaluronic acid (HA, Supplementary 
Methods) whose increase partially reflects the degree of SEC dysfunction or release from 
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the surface glycocalyx of SECs during post-ischemic reperfusion. Following 60min 
ischemia and 15min reperfusion, serum HA increased strikingly compared to sham-operated 
mice (Fig.1Bii) reflecting very early release from SECs during reperfusion. 
 
In order to establish the nature of MPs that circulate during hepatic IRI, we first used 
FACS gating to determine their size. We then partially characterized their cells of origin by 
incubation with fluorescent-labeled mAbs directed at molecules specific or relatively 
specific (in the case of CD62P) to different cell types (S22, Supplementary Table 1). MPs 
obtained post-IRI varied from 0.45 - 1m (Fig.1C). MPs appeared to be released in a time-
dependent manner during post-ischemic reperfusion (Fig.1A), and like serum ALT increase, 
reached peak levels at 24hrs reperfusion (Fig.1A,1Bi). MPs produced early (15, 30min) in 
reperfusion were enriched for endothelial cell (CD144, CD62P for activated SECs), platelet 
(CD41, CD62P also for activated platelets) and neutrophils (Ly6G) markers, indicating 
predominant origins from SECs, platelets and neutrophils. In addition, NK-T cell (CD1d 
tetramer) and CD8 T-cell markers were also expressed (Fig.1Ci). By 2hr reperfusion, 
markers of Kupffer cells/macrophages (F4/80) were more conspicuous on MPs (Fig.1Ci,ii), 
while NK-T cells and CD8 markers diminished (Fig.1Ci).  To confirm co-location of cell-
specific markers with 0.45 - 1m  MPs (excluding most apoptotic bodies – see earlier), we 
established that subsets of MPs released post-IR double stained positive for Annexin V, as 
well as CD144, CD41, CD62P, F4/80 and Ly6G (Fig.1Cii). 
 
As an additional approach to MP cell-source characterization, we performed 
immunoblot analysis of MP proteins. At 15min reperfusion, VE-cadherin, E-selectin 
(endothelial cell proteins) and vascular adhesion molecule (VCAM-1) were detected 
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(Fig.1D,E). By 30min, P-selectin (platelets) and ICAM-1 were also detectable. At 2hr, all 
the above proteins were substantially enhanced in MPs, with a dramatic increase in 
hepatocyte-specific asialoglycoprotein-receptor (ASGPR) as well as VE-cadherin 
(Fig.1D,E).  
 
MPs shed during post-ischemic reperfusion contain bioactive lipids 
As expected from their plasma membrane origin, MPs contain 
lysophosphatidylcholine (lysoPC), arachidonic acid (AA) metabolites and oxysterols (S23-
S25). Because of their potential relevance to inflammation and coagulation, we assayed the 
following bioactive lipid species within MPs obtained during the early phase (15min, 2hr) 
of post-ischemic reperfusion: (i) AA metabolites – prostaglandins, leukotrienes, 
hydroxyeicosatetraenoic acid , epoxyeicosatrienoic acids, F2-isoprostanes, (ii) specific 
phospholipids namely lysoPC, platelet activating factor (PAF), lysoPAF, PS, PE, and (iii) 
cholesterol oxidation products (oxysterols). At both reperfusion times, samples contained a 
range of fatty acids (palmitic, stearic, oleic, linoleic). Whereas MPs at 15min (ultra-early) 
reperfusion contained only a trace of AA, those at 2hr were enriched with AA (3.6µg total 
or 6g/mg protein). Samples also contained increased F2-isoprostanes derived from free 
radical oxidation of AA: at 15min, 0.40ng; 2hr, 0.44ng (Fig.1F) compared to those derived 
from sham-operated mice.  Thus, MPs released during the first 2hr of post-ischemic 
reperfusion contain several lipid molecules known to trigger inflammation and injury.  
 
MPs generated during hepatic IRI promote neutrophil migration and activate platelets 
 In order to test our hypothesis that MPs originating from SECs, inflammatory cells 
and platelets incite the early inflammatory/injury response in IRI (10,17), we tested whether 
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circulating MPs isolated in these experiments could to promote neutrophil recruitment. 
Addition of MPs generated by IRI (Fig.2Ai), as well as those from specific cell types 
(Fig.2Aii, particularly CD62P: activated platelets, F4/80: macrophages) to these chambers 
enhanced transmigration of leukocytes obtained from normal mouse liver in a dose-
dependent manner. In contrast, MPs pre-treated with N-acetylcysteine (NAC), a ROS and 
reactive nitrogen species scavenger, inhibited leukocyte transmigration in response to MPs 
(Fig.2Ai).  Because the overall neutrophil responses elicited by cell-specific subtypes of 
MPs were similar to those from the ‘mixed’ pool of MPs derived at 2hr reperfusion, we 
used the latter for subsequent studies. Such MPs activated platelets derived from sham-
operated mice as shown by enrichment of CD62P (activated platelets) in relation to CD41 
(all platelets)(S26) compared to PBS-treated controls (Fig.2B). Collectively, these findings 
are consistent with our hypothesis that MPs liberated during liver IR from SECs and other 
cell types induce neutrophil migration and activate platelets. 
 
MPs generated during hepatic IRI induce injury in primary hepatocytes by a process that 
involves oxidative stress and mitochondrial membrane permeability transition 
Because of their bioactive lipid content and potentially reactive oxygen 
intermediates and other pro-oxidants, MPs could also be directly cytopathic to hepatocytes. 
If so, this could, at least partially, contribute to the presence of hepatocyte-specific markers 
(ASGPR-positive) on MPs that circulate 2 and 24hr post-IR. To test this, we incubated 
primary murine hepatocytes (cultured in Williams E media) with MPs isolated from mice 
subjected to ischemia/2hr reperfusion. Within 30min, these MPs adhered to hepatocytes, 
while endocytosis clearly evident by 1hr (Fig.2C). This uptake process was inhibited by 
hypertonic sucrose (0.45M) which blocks endocytosis (Fig.2C)(S27). Following engulfment 
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of MPs (and not in control hepatocytes to which vehicle alone was added), hepatocyte 
injury was evident by LDH leakage (Fig.2D). Such MP-induced hepatocyte injury was 
particularly striking for F4/80 positive-MPs, which is consistent with the proposed role of 
KCs in hepatic IRI (Fig.2E).   
 
 To elucidate the mechanism by which IRI-related MPs injure hepatocytes, we used 
confocal microscopy of TMRM fluorescence (S28) to show how addition of MPs caused 
MPT, a phenomenon blocked by cyclosporine A (CyA)(Fig.3A). Further, we observed 
evidence of oxidative stress in MP-treated primary hepatocytes which could be abrogated by 
the antioxidant, N-acetylcysteine (NAC) in DCFH2-DA studies (Fig.3B). Thus, MPs induce 
oxidative stress in hepatocytes and provoke MPT whilst primary hepatocytes can be 
‘rescued’ from MP-related injury by co-treatment with an antioxidant or MPT inhibitor.  
 
 The effect of NAC on MPs release was further clarified by administering this potent 
antioxidant to mice (150mg/kg ip, Supplementary Methods) 5min prior to 60min ischemia 
and 24hr reperfusion. NAC significantly inhibited MP release and was profoundly 
hepatoprotective against IRI compared to naïve mice (Supplementary Fig.1A,B). Moreover, 
NAC greatly diminished the oxidative potential of MPs in primary hepatocytes and in vivo, 
as shown by a marked reduction in glutathione oxidation (oxidized glutathione/reduced 
glutathione, GSSG/GSH, Supplementary Fig.1C,D). 
 
MPs initiate post-ischemic inflammatory responses by activating NF-B in hepatocytes 
To further define their pro-inflammatory potential, MPs from mice subjected to IRI 
(as well as those derived from primary hepatocytes subjected to hypoxia-reoxygenation 
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[HR], described later), were probed for adhesion molecules. As mentioned earlier, MPs 
isolated at 15min reperfusion bear appreciable VCAM-1, E-selectin and P-selectin, while 
ICAM-1 is expressed on MPs shed at 30min reperfusion, and VE-cadherin is detected at 2 
and 24hr (Fig.1D,E). Thus, the profile of pro-inflammatory adhesion molecules borne on 
MPs differs with reperfusion time. Further, it recapitulates the suite of different adhesion 
molecules known to be expressed in livers subject to IRI (1-6). 
 
 Addition of MPs to primary hepatocytes likewise induced ICAM-1 and VCAM-1, and 
up-regulated pro-inflammatory COX-2 and PKC- protein expression (Fig.3C,D). MPs also 
activated c-jun N-terminal kinase (JNK)(Fig 3E), a known mediator of hepatocyte injury in 
IRI (1-6). To establish the effects of MPs on NF-B activation, we determined degradation 
of cytosolic IB-, and show that MPs caused a dose-dependent decrease in IB-α (Fig.3F). 
 
Hypoxia-reoxygenation leads to MP formation from primary hepatocytes by an oxidative 
stress and calcium-dependent process  
 In order to simulate the in vitro conditions for MP formation relevant to hepatic IRI in 
vivo, we exposed primary hepatocytes to 4hr hypoxia followed by 24hr reoxygenation. This 
liberated MPs, whereas hepatocytes subjected to normoxia alone did not (Fig.4A). CyA 
significantly diminished MP release after HR and markedly reduced cell injury (Fig.4B). To 
establish more directly that oxidative stress is responsible for MP generation, we incubated 
primary murine hepatocytes from mice with escalating doses of H2O2. At 20M or higher, 
H2O2 caused generation of MPs from primary hepatocytes (Fig.4C), a process abrogated by 
addition of 1mM EGTA, a potent Ca
2+
 chelator (S28), thereby abrogating activity of Ca
2+–
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dependent proteases such as calpain. These findings suggest that MP release from 
hepatocytes is triggered by oxidative stress and is Ca
2+
-dependent.  
 
TNF augments JNK-dependent MP formation by primary hepatocytes, as well as in mice 
after IRI 
TNF levels increase strikingly during liver IR, and an injection of high dose TNF 
prior to IR exacerbates liver injury (2,8) as well as SEC dysfunction by serum hyaluronic 
acid release (Fig.5A). TNF is a potent agonist of endothelial MP vesiculation and 
contributes to MP production in vitro (S29). It is therefore of interest to establish whether 
MPs stimulate TNF release in primary hepatocytes. As shown in Fig.5B, addition of 30 and 
60nM of MPs for 1hr under normoxic conditions provoked at least 4-fold stimulation of 
TNF production from hepatocytes. Conversely, incubating primary hepatocytes with 2nM 
TNF triggered perceptible MP production at 1hr, increasing significantly by 24hr, by a 
process abrogated by addition of SP600125 at concentrations for which it is a specific JNK 
inhibitor (Fig.5C). Finally, to establish whether TNF has similar effects on MP release in 
vivo, we injected murine TNF intravenously (5g/kg) 5min prior to onset of 60min 
ischemia, then measured MP production. The results show that TNF augments MP 
production in vivo during hepatic IR (Fig.5D), reaching a maximal response at 2hr 
reperfusion.  
 
The annexin V-homodimer, ASP8597 (Diannexin) inhibits MP production after hepatic 
IRI and reduces platelet activation  
Because Annexin V efficiently binds to MPs (most likely to everted PS 
residues)(S22), we investigated whether such a strategy would also block MP production 
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(Fig.6A) and prevent hepatic IRI. Diannexin is a biosynthesized human recombinant 
homodimer of annexin V that exerts considerable hepatoprotection against IRI in our 
murine model (Fig.6Bi); its efficacy associated with reduced swelling and detachment of 
SECs from their basement membrane, decreased hepatic expression of pro-inflammatory 
ICAM-1, VCAM and MIP-2, and abrogated leukocyte and platelet adherence to SECs 
(9,10). To establish whether this protective action involves attenuation of MP release, we 
injected mice with Diannexin (1mg/kg), 5min prior to hepatic ischemia and measured MP 
production during reperfusion. At all timepoints, Diannexin significantly diminished MP 
release, liver and SEC injury (by serum ALT and HA respectively) compared to naïve mice 
(Fig.6Bi,1Bii, Table1). By FACS, Diannexin not only substantially reduced MP production, 
it also altered the profile of cell markers detected on the residual trivial quantities of MPs 
derived (Fig.6A vs Fig.1C). Thus, these residual MPs displayed reduced markers for 
endothelial cells (CD144), platelets (CD41) and activated platelets (CD62P)(Fig.6A) 
confirming our proposal that the major effect of Diannexin is on SECs and platelets, and 
occurs early during post-ischemic reperfusion (10). Further, the protective efficacy and 
suppression of MP production conferred by Diannexin is sustained into late reperfusion 
(Fig.6Bi).  
 
Incubation of platelets derived from sham-operated mice with MPs isolated from 
mice after 60min ischemia/2hr reperfusion resulted in a significant induction of activated 
(CD62P+ve) platelets (Fig.6Bii). However, if such MPs were “Diannexin-treated” (4g/ml) 
then exposed to ‘normal’ platelets in vitro, this strategy yielded significantly reduced 
populations of CD62P+ve platelets compared to those exposed to “Diannexin-naïve” MPs 
(Fig.6Bii) 
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Diannexin blocks the pro-inflammatory and pro-oxidant properties of MPs released 
during hepatic IRI 
 While Diannexin reduced total MP production after IRI, the attendant abrogation of 
liver injury by ALT (Fig.1Bi) and histology was even more complete (10). This would be 
explained if MP production was only part of the hepatoprotective effect of Diannexin, or if 
residual MPs failed to exert their pro-inflammatory and platelet-activating properties. To 
test the latter proposal, MPs from Diannexin-treated animals subjected to IRI were analyzed 
for the expression of hepatocyte-specific marker ASGPR, and inflammatory adhesion 
molecules, VCAM-1, ICAM-1 and E-selectin by immunoblotting. MPs from Diannexin-
treated mice yielded significantly reduced markers for cells of hepatocyte origin (Fig.6C,D). 
While VCAM-1, ICAM-1 and E-selectin were strikingly upregulated in MPs released in 
naïve mice during late reperfusion (24hr)(Fig.1D,E), their expression was significantly 
mitigated after Diannexin treatment (Fig.6C,D). In in vitro experiments, incubation of MPs 
isolated from mice after 60min ischemia/2hr reperfusion with Diannexin in vitro, markedly 
inhibited leukocyte transmigration potential in chemotaxis studies (Fig.6E).  
  
 The oxidation status of MPs derived from Diannexin-treated mice was determined by 
oxidized glutathione/reduced glutathione (GSSG/GSH) measurements. As depicted in 
Supplementary Fig.1C, glutathione oxidation was significantly diminished by Diannexin-
pretreatment compared to levels in MPs derived from naïve mice. Taken together, this suite 
of interventions confirm that Diannexin effectively abrogates cell-specific injury 
particularly to SECs, hepatocytes, reduces platelet-activation, the pro-inflammatory and pro-
oxidant properties of MPs liberated during liver IR and that these findings strongly correlate 
with hepatoprotection by serum ALT (Fig.6Bi) . 
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 DISCUSSION  
  MPs are cell membrane fragments shed upon injury or apoptosis whose circulating 
levels have been reported as biomarkers for such vasculopathies as acute myocardial 
infarction, ischemic stroke, peripheral vascular disease and eclampsia (11-13). In the present 
study, we first established that MPs are liberated during hepatic IRI, arising in the earliest 
stages from activated or injured SECs, and in the later phases, involving platelets, various 
inflammatory cells and eventually hepatocytes. We then demonstrated that MPs actively 
contribute to the pathogenesis of IRI via their well-known pro-inflammatory effects and 
their role as platelet-activating agents. We also provided evidence for an entirely novel 
pathway of direct hepatocyte injury in IRI. Finally, our novel findings clarify the 
mechanism for the powerful therapeutic efficacy of the annexin V dimer, Diannexin, which 
would be expected to “seek and hide” exposed PS residues on circulating MPs (10). 
  
  MPs are released within minutes of IR or hypoxia-reoxygenation. This is followed 
by further cascades of shedding from a variety of cell types over several hours. Although the 
present data are confined to small MPs (0.45 – 1 m) that comprise exosomes rather than 
apoptotic bodies, it is possible that larger MPs (aptosomes) also play a role in IRI, as might 
lipid rafts and smaller MPs. This requires further study using newer technology for MP 
purification. However one of the major new findings of the present studies is that circulating 
MPs are engulfed by hepatocytes, and this causes ROS generation with induction of MPT as 
a pathway to cell injury and necrotic cell death. In keeping with reports in other cell types 
(12,13), our results also provide direct evidence that hepatocyte-derived MPs cause dose-
dependent TNF release from other hepatocytes, a process that is ROS-dependent and can be 
abrogated by NAC in vivo and in vitro. This is potentially important in propagation of liver 
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IRI as TNF further amplifies MP shedding in vivo during hepatic IRI, also by a redox and 
calcium-dependent process.  Interruption of TNF release with NAC, an agent already in use 
in clinical practice for acetaminophen overdose, so as to mitigate propagation of liver IRI is 
worthy of further study in humans after hepatic surgery or liver transplantation.  
 
  The phospholipid composition of each leaflet of the plasma membrane bilayer differs; 
PS and PE aggregate in the inner leaflet, PC and sphingomyelin are present in the outer 
layer (17). Loss cellular energy, or after cytoskeletal disruption (as in apoptosis) leads to 
loss of membrane integrity with eversion of the negatively charged PS and PE. Hence, MPs 
liberated after cellular injury usually bear PS on their extruded surfaces. Other lipid 
molecules with biological activity are contained within MPs including lysoPC, AA 
metabolites (including F2-isoprostanes) and oxysterols. Both the nature of cellular insult 
and the cell type of origin influence MP constituents (11,S22). In our studies, MPs 
generated after 15min reperfusion contained only a trace of AA, but the amount escalated 
by 2hr reperfusion, and at this time highly pro-inflammatory F2-isoprostanes could also be 
detected. The nature of our studies in the whole mouse does not allow clarification of why 
MP lipid composition changes post-ischemic time, other than to note that AA and F2-
isoprostanes which were detected at 2hr but only in vanishingly small quantities at 15min, 
were more likely to arise from platelets and macrophages rather than SECs, other 
inflammatory cells and hepatocytes. 
 
   In order to understand how MPs could exert pro-inflammatory effects, as 
demonstrated by the neutrophil migration studies, we probed MP pellets for adhesion 
molecules. As early as 15min reperfusion, circulating MPs express VCAM-1, E-selectin and 
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P-selectin (Fig.1D), while ICAM-1 and VE-cadherin were detected later. Further, our in 
vitro approaches demonstrated unambiguously that the MPs which circulate during post-
ischemic reperfusion with the most potent pro-inflammatory properties are KC/macrophage- 
and platelet-derived. The present results clearly indicate that MPs engulfment by 
hepatocytes leads to degradation of IκB-α, the cytosolic inhibitor of NF-B. Activation of 
NF-B in livers subjected to IR upregulates numerous pro-inflammatory genes such as 
COX-2 and PKC- that participate in liver inflammatory recruitment and cell death 
(2,3,5,6). These effects were observed in the context of MP stimulation, together with 
elaboration of TNF and activation of JNK, both of which are known pro-inflammatory 
pathways in hepatic IRI injury (8,S30). Thus, in addition to direct effects of redox stress, 
TNF and JNK activation, MP engulfment is another node in the pathways to pro-
inflammatory signaling during IRI. Importantly, as already mentioned, this is another site at 
which NAC could exert therapeutic effects. 
  
  The formation of membrane-derived MPs is dependent on increased intracellular ionic 
calcium which activates calpain. We and others have shown that hepatic calpain activity 
escalates with increasing post-ischemic reperfusion time (Supplementary Fig.2) and calpain 
inhibition by calpeptin significantly reduced MP production in the present experiments 
(S31). Whether agents to sequester mobilisation of ionic calcium or calpain antagonists 
could have therapeutic application in hepatic IRI requires further study. Our previously 
ultrastructural studies revealed extensive blebbing of the sinusoidal endothelium at 30min 
post-ischemic reperfusion (10). The present results show this is the origin of the MPs that 
circulate within 15 min of hepatic IRI. This potentially does have therapeutic implications 
for early intervention in IRI. Thus, we addressed the suggestion of Albano (17) that 
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Diannexin, by binding to PS, might inhibit MP release, thereby interfering with the 
inflammatory and procoagulant effects normally executed by MPs. This was shown 
unambiguously to be the case. Moreover, residual MPs from Diannexin pre-treated mice 
displayed less pro-inflammatory and pro-oxidant potential and activity. Lipid rafts of the 
cell membrane may also play a role in MP release (S32); annexin V is known to bind to 
lipid rafts of cells and to PS with high affinity (S33). It is therefore also plausible that 
Diannexin, by binding to lipid rafts, prevents the distortion of the plasma membrane surface 
that is a pre-requisite for vesicle-budding to form MPs.  
 
  In summary, our data indicate that MPs are released during liver IRI and that these 
MPs are pro-inflammatory, platelet activating, and directly pathogenic to hepatocytes in 
vitro. By simulation experiments, we have shown that MP production, at least in 
hepatocytes, is modulated by oxidative stress, TNF and calcium fluxes, known pathogenic 
factors in IR. Not all MPs are the same; by selective study of cell-derived MP subfractions, 
we showed those from KCs/macrophages and platelets may be particularly pro-
inflammatory and particularly injurious to hepatocytes. Whether this is due to higher AA 
and F2-isoprostane content requires further investigation. Meanwhile, the clear finding that 
Diannexin protects against MP production and MP-induced injury has therapeutic 
implications. Thus, we have already shown that Diannexin exerts both preventive and 
therapeutic effects against hepatic IRI, the latter up to 24 hrs after post-ischemic liver 
reperfusion (10). Taken together, the present results reveal pivotal pathogenic mechanisms 
that initiate and likely perpetuate hepatic IRI during liver surgery and transplantation. 
Implication of MP formation should facilitate the development of clinically applicable and 
effective strategies against IRI.  
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FIGURE LEGENDS 
Figure 1 
MP production is increased in hepatic IRI 
A. MP release (concentration expressed as phosphatidylserine, PS equivalent in nM) and 
Bi,ii serum ALT and hyaluronic acid (HA) after 60min ischemia and indicated reperfusion 
times in naïve and Diannexin-treated mice (n=10 per cohort). 
* p<0.05 all experimental groups vs. sham 
‡ p<0.05 IRI 2hr vs. 30min reperfusion 
# p<0.05 IRI 24hr vs. 15min, 30min and 2hr reperfusion 
§ p<0.05 Diannexin vs. no Diannexin at 24 hr reperfusion 
C. FACS plots demonstrating MPs released early in reperfusion are composed 
predominantly of endothelial-derived/CD144 remnants while in late reperfusion, MPs are 
largely from leukocytes and hepatocytes. (Ci) FACS data depicted as % bearing cell-
specific markers (Supplementary Table 1). Note, because individual MPs are cell fragments 
and may potentially fuse, MPs can bear more than 1 cell-marker and therefore, the sum of 
all expressed markers may feasibly exceed 100% (Supplementary Methods). (Cii) Annexin 
V was utilized to analyze for double positive events together with cell-specific markers 
CD144, CD41, CD62P F4/80 and Ly6G. * p<0.05 IRI groups vs. sham 
D. MPs bear ASPGR (hepatocytes) and VE-cadherin (SECs), VCAM-1, ICAM-1, E-
selectin, P-selectin. MPs obtained from mice subjected to liver post-IR at indicated times.  
Blots representative of three similar experiments.  
E. Image analyses/quantification show upregulation of adhesion molecules especially at 2, 
24hr reperfusion.  
* p<0.05 IRI vs. sham 
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& p<0.05 IRI 2 and 24hr vs. IRI 15 and 30min reperfusion 
%p<0.05 IRI 30min vs. IRI 15min reperfusion 
# p<0.05 IRI 24hr vs. 15,30min, 2hr reperfusion 
§ p<0.05 IRI 2hr vs. 15min reperfusion   
‡  p<0.05 IRI 2hr vs. IRI 30 min reperfusion 
F. MPs at 15min and 2hr reperfusion contain increased levels of F2-isoprostanes compared 
to those derived from sham-operated mice by GCMS and LC/MS/MS (normalised to total 
AA detected).  
 
Figure 2 
MPs are directly pathogenic to primary hepatocytes, incite neutrophil recruitment and 
activate platelets 
Ai. Hepatic neutrophils were derived by liver perfusion and chemotaxis measured in 
ThinCert
TM
 chambers. Lower compartments were seeded with MPs from mice subjected to 
2hr post-ischemia-reperfusion (IR), IL-8 or TNF- as chemoattractants (IL-8,TNF:positive 
controls) and incubated (1hr, 37°C). Co-treatment of MPs with 1mM NAC reduced 
neutrophil transmigration. To ascertain effect of N-acetylcysteine (NAC) on transmigration 
potential, MPs were pre-treated with 1mM NAC for 1hr 37°C; thereafter, MPs were 
resuspended in PBS then recovered by prolonged centrifugation (see Supplementary 
Methods for detailed MP isolation protocol) prior to the transwell migration assay.  
Aii.  Addition of MPs generated by IRI from specific cell types (significantly, activated 
platelets and endothelial cells [CD62P], and macrophages [F4/80]; not resting SECs 
[CD144]) to these chambers enhanced transmigration of leukocytes. * p<0.05 experimental 
groups vs. control 
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B. Platelets from sham-operated mice treated with 60nM MPs (from mice subjected to 2hr 
post-IR) for 30min, labelled with CD62P (activated platelet and endothelial cell marker) and 
subjected to FACS. * p<0.05 experimental groups vs. control 
C. MPs from mice subjected to 2hr post-IR co-incubated with primary hepatocytes. By 
30min, MPs adhered to hepatocytes and were endocytosed at 1hr (first row/top panel of 
figures: 0min, 30min, 60min); engulfment was inhibited by 0.45M sucrose (second 
row/lower panel of figures: 30min, 60min). 
D. Primary hepatocytes treated with increasing concentrations of MPs derived from mice 
subjected to 2hr post-IR. LDH leakage and cell viability (MTT assay) in MP-treated cells 
compared with PBS-controls. (E) Primary hepatocytes treated with increasing 
concentrations of MPs derived from specific cell types (CD62P: activated platelets and 
endothelial cells, CD144: SECs, F4/80: macrophages) obtained from mice subjected to 2hr 
post-IR. 
Experiments performed in triplicate in MP-preparations from 4 mice (n=12). *p<0.05 
experimental groups vs. control 
 
Figure 3 
MPs invoke mitochondrial permeability transition, oxidative stress, adhesion molecule 
expression and activate NF-B in hepatocytes 
A. Hepatocytes loaded with 50nM TMRM (red fluorescence), 1M DCFH2-DA (green 
fluorescence) and placed in chambers at 37°C for 15min. MPT occurred with increasing MP 
concentrations, blocked by 1M CyA.  
B. 1mM of NAC inhibited oxidative stress generated by MPs. 
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C, D. Primary hepatocytes were exposed to 60nM of MPs derived from liver 2hr post-IR 
and pro-inflammatory molecules COX-2 and PKC-determined (WB) as well as (E) JNK-
1/2 (46kDA, 54kDA) activation (phospho-JNK). 
* p<0.05 experimental groups vs. control 
+ p<0.05 30 and 60nM vs. 12nM MPs 
† p<0.05 MPs 60nM vs. 30nM MPs 
F. MPs activate NF-B in primary hepatocytes, by IκB-α degradation (immunoblots). Blots 
represent three experiments conducted in triplicate (n=9). 
* p<0.05 experimental vs. control 
 
Figure 4 
Hypoxia-reoxygenation and oxidative stress trigger MP release 
A. Primary hepatocytes were exposed to 4hr hypoxia followed by 24hr reoxygenation 
(Methods). Pretreatment with 1M CyA (MPT-inhibitor) for 2hr prior to HR attenuated MP 
release and (B) LDH leakage from hepatocytes subjected to HR. Controls: cells incubated in 
normoxic conditions. Experiments performed in triplicate.  
* p<0.05 experimental vs. control 
& p<0.05 hypoxia-reoxygenation  vs. CyA  
C. H202 causes MP primary hepatocytes to form MPs, which is attenuated by calcium 
chelation (EGTA) . Primary murine hepatocytes were incubated with H202 for 24hr. At 
10M or higher, H202 causes generation of MPs, while MP release is abolished by co-
administration of EGTA. Assays performed in triplicate.  
* p<0.05 experimental vs. control 
+p<0.05 EGTA vs. H202  
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Figure 5 
MPs stimulate TNF release and are themselves potent agonists of MP vesiculation in 
vivo 
A. Serum hyaluronic acid (HA) release increases in mice subjected to 60min ischemia and 
15min reperfusion; this is exacerbated by administration of TNF in vivo (mice injected with 
TNF 5g/kg iv vs. saline controls), 5min prior to 60min ischemia. 
* p<0.05 experimental vs. control 
B. TNF is produced by primary hepatocytes following addition of MPs derived from mice 
subjected to 2hr post-ischemic reperfusion. 
* p<0.05 experimental vs. control  
† p<0.05 60nM vs. 30nM MPs 
C. Primary hepatocytes were incubated with 2nM TNF for 1hr and 24hr in normoxic 
conditions.  SP600125 (20M in 0.1% DMSO) significantly attenuated TNF-stimulated MP 
release .  
* p<0.05 experimental vs. control 
‡ p<0.05 TNF vs. TNF+SP600125 
D. WT CL57BL6 mice were injected i.v. with TNF 5g/kg (saline for controls), 5min prior 
to 60min ischemia. MP production was measured in plasma at 15min, 30min, 2hr 
reperfusion. Liver IRI triggered MP production; TNF injection further augmented MP 
release reaching a maximum at 2hr. 
* p<0.05 experimental vs. control 
± p<0.05 IRI groups vs. sham TNF  
# p<0.05 30 min+TNF vs. IRI 30 min reperfusion 
§ p<0.05 2 hr+TNF vs. 2 hr reperfusion 
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Figure 6 
Diannexin attenuates release of MPs after hepatic IRI and decreases their pro-
inflammatory and deleterious potential  
MPs were obtained from mice pre-treated with 1mg/kg iv Diannexin 5min prior to 60min 
liver IR and results compared with vehicle-treated/naïve mice subject to IR. 
A. FACS revealed significantly reduced resting endothelial cell (CD144), resting platelet 
(CD41) and activated platelet and endothelial cell (CD62P) subsets compared to naïve (see 
Fig.1C).  
Bi. Serum ALT after 60min ischemia and indicated reperfusion times in naïve and 
Diannexin-treated mice (n=10 per cohort). 
* p<0.05 all experimental groups vs. sham 
§ p<0.05 Diannexin vs. 24 hr reperfusion 
Bii. Platelets were isolated from sham-operated mice and exposed to 60nM MPs (derived 
from mice subjected to 60min ischemia, 2hr reperfusion) in the absence or presence of 
4g/ml Diannexin. FACS then performed using CD62P to quantify activated platelet subset 
as a proportion of total platelets. 
* p<0.05 experimental vs. control 
# p<0.05 Diannexin vs. 60nM MPs 
 C, D. Hepatocyte-specific ASPGR, E-selectin and pro-inflammatory VCAM, ICAM-1 
protein expression diminished by Diannexin compared to naïve mice subjected to 60min 
ischemia and indicated reperfusion times.  
+ p<0.05 Diannexin vs. sham  
& p<0.05 Diannexin vs. naïve 
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E. Pre-treatment of MPs with Diannexin 4g/ml inhibited neutrophil transmigration in 
ThinCert
TM
 chambers. To ascertain effect of test compounds on transmigration potential, 
MPs were pre-treated with Diannexin (4g/ml) for 1hr 37°C; thereafter, MPs were 
resuspended in PBS then recovered by prolonged centrifugation twice (see Supplementary 
Methods for detailed MP isolation protocol) prior to the transwell migration assay.  
 
* p<0.05 experimental vs. control 
# p<0.05 Diannexin vs. 60nM MPs 
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TABLE 
Table 1  
Microparticles released at indicated reperfusion time after 60min hepatic ischemia in 
naïve and Diannexin-treated mice (n=10 per experimental group) 
 
 
 
 
*p<0.05 all experimental groups vs. sham 
@p<0.05 Diannexin vs. 15min reperfusion 
& p<0.05 Diannexin vs. 30min reperfusion 
# p<0.05 Diannexin vs. 2hr reperfusion 
§
 
p<0.05 Diannexin vs. 24hr reperfusion 
 
 
 
 
 
 
 
 
Experimental group, 
and reperfusion time 
Microparticles released (PS equivalent, nM) 
Naϊve Diannexin 
Sham 14.7 ± 5.52 12.5 ± 1.57 
15 min  48.1 ± 12.6  * 29.9 ± 3.25 * 
@
 
30 min  34.7 ± 12.8 * 20.1 ± 5.77 
&
 
2 hr  51.9 ± 10.9 * 35.2 ± 3.42 * 
#
 
24 hr 104 ± 25.6 * 44.8 ± 9.43 * 
§
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